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1. Pneumonia increases the risk of venous thrombosis. (this thesis) 
2. Modifying the winter season to summer season will not substantially lower 
the frequency of venous thrombosis in the Netherlands or Norway. (this thesis)  
3. Synergistic effects of common acquired and congenital risk factors for 
venous thrombosis have a major impact. (this thesis) 
4. The identification of individuals with low free protein S or low total 
protein S levels will only rarely could at best rarely identify subjects at risk 
for venous thrombosis in a population based study. (this thesis) 
5. Information on exposure to risk factors for venous thrombosis long before 
the first event does not provide useful information to classify patients at 
reduced risk for recurrence of venous thrombosis. (this thesis)  
6. Thrombophilic abnormalities are present in many patients with venous 
thrombosis. However, thrombophilia testing in all patients with a first venous 
thrombosis is neither clinically feasible nor useful. (this thesis)  
7. Venous thrombosis is a multicausal disease. (Frits Rosendaal. Lancet 1999)  
8. Accuracy of prevention strategies for recurrent venous thrombosis may be 
improved by including venous thrombosis associated with a transient 
infection in the current definition of “provoked” event. (Jasmijn F. Timp. 
British Journal of Haematology 2017)  
9. Despite the increasing knowledge about the etiology of venous thrombosis, 
testing for thrombophilia serves only a limited purpose and should not be 
performed on a routine basis. (Saskia Middeldorp. Hematology 2011)  
10. Epidemiology makes headlines more often than most other sciences. Every 
time you hear that something is good for you or bad for you, either there is an 
epidemiological study involved, or there is an epidemiological study being 
planned to check whether the claim is true. (If neither of these is the case, you 
should get your news somewhere else.) Yet many people have never heard of 
epidemiology. (Alex Broadbent. Philosophy of Epidemiology 2013) 
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GENERAL	  INTRODUCTION	  
The overall incidence of venous thrombosis is 1-2 per 1000 persons each year 
and rises exponentially from < 0.005% in children to 1% per year in the 
elderly [1]. Most venous thrombosis start in the calf veins, from where they 
may extend and cause proximal deep vein thrombosis, and subsequently 
pulmonary embolism [2]. Patients with deep vein thrombosis or pulmonary 
embolism remain at risk for recurrent venous thrombosis. This risk is most 
pronounced in the first months after the acute episode and declines slowly 
over subsequent years [3]. Known risk factors for venous thrombosis are 
presented in Table 1. Although the existence of this long list of risk factors 
may seem reassuring, it does not come close to give us all the answers: many 
people have several of these risk factors but never develop thrombosis; others 
suffer from thrombosis but have none. Therefore, the challenge that we are 
facing today is not to just add more risk factors to this list but rather to 
integrate them all in a causal model that allows us to understand how and 
when thrombotic disease develops in an individual. Such a causal model for 
venous thrombosis was first described in 1999 by Rosendaal [4], and was 
coined as “the thrombosis potential model”. The idea behind this model is that 
an individual is at risk for venous thrombosis throughout life, which is 
reflected in the ‘thrombosis potential’ and that each risk factor contributes to 
increase the potential. Only when the combination of thrombosis risk factors 
reach a certain potential, venous thrombosis will occur (crossing of the 
thrombosis threshold). A worked out example is given in Figure 1. The black 
lines in the figure represent the thrombosis potential of each separate risk 
factor for a particular individual, and the grey line the thrombosis threshold. 
The horizontal axis shows time (i.e. the age of the individual). As the 
thrombosis potential is age-dependent, based on the observation that the 
incidence of thrombosis increases with age [5], the black line increases 
through time. Consider a person who has factor V Leiden (person A) and a 
person with blood group non-O (person B). Factor V Leiden carriers have a 5-
7 fold increased risk of venous thrombosis [6], while blood group non-O is 
associated with a 1.5-fold increased risk [7]. So, person A has a larger 
inherited thrombosis potential than person B. They are of similar age, i.e., 55 
years old. At this age, person A encounters a short period of immobilisation 
due to a strained ankle. In this example, this short period of a high thrombosis 
potential exceeds the thrombosis threshold and consequently leads to deep 
vein thrombosis (in the absence of anticoagulant prophylaxis, which would 
substantially decrease the potential). For person B, however, a similar acquired 
risk factor has not led to a thrombosis potential exceeding the thrombosis 
threshold. Therefore, this person does not develop the disease at this age. 
In this thesis, the thrombosis potential model will be applied to several known 
risk factors for venous thrombosis to better understand why first and recurrent 
venous thrombosis can develop in an individual patient.  
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Although several studies have focused on infectious diseases as possible 
causes of arterial thrombosis [8,9], less is known about their role in the 
development of venous thrombosis. According to Virchow’s triad, infections 
could affect blood flow, damage the vessel wall or increase coagulability of 
the blood [10]. It is therefore interesting to note that a prospective 
population-based cohort study showed that elevated C-reactive protein 
levels, a marker of inflammation,  were associated with an increased risk of 
venous thrombosis [11]. This risk was highest when C-reactive protein levels 
were elevated during the period directly prior to the onset of venous 
thrombosis. This finding supports the hypothesis that the coagulation system 
can be stimulated by transient inflammatory processes such as infections. 
Although two retrospective cohort studies showed that patients with 
pneumonia had a 2- to 3-fold elevated risk of acute venous thrombosis 
[12,13], there is uncertainty over the extent to which this risk association is 
causal. Pneumonia is often accompanied by transient periods of 
immobilization or hospitalization, leading to venous stasis that could explain 
the association. Alternatively, lifestyle could confound the association, when 
habits such as smoking and physical activity are related to both risk of 
pneumonia and risk of venous thrombosis. In Chapter 2, we elaborate 
whether the risk of venous thrombosis in patients with pneumonia is 
influenced or explained by immobility or unhealthy lifestyle factors, or that 
transient pneumonia can be seen as the final trigger that leads to the crossing 
of the thrombosis threshold. 
	  
Seasons	  
Seasonal variation in the incidence of various diseases, mainly characterised 
by a winter peak, has been reported for acute myocardial infarction and 
sudden cardiac death [14], and for ischemic and hemorrhagic stroke [15]. 
Although circannual variability of venous thrombosis has been reported 
since 1939, results of the reported studies are conflicting [16,17]. 
Nevertheless, the reported association between the seasons and the incidence 
of venous thrombosis is supported by studies showing that cold temperature 
is associated with increased levels of coagulation factors [18]. Also, transient 
General introduction and outline of the thesis 
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infections (such as pneumonia or influenza) are more common in the colder 
seasons of temperate climates, which may also increase the risk of venous 
thrombosis [13]. Furthermore, air pollutants are more common in winter 
months than in spring, specially in larger city areas [19]. Finally, vitamin D, 
synthesized in the skin after sun exposure, has been related to fibrinolytic 
and procoagulant activity [20]. Therefore sun exposure during the summer 
months may consequently lower the risk of thrombotic events. So, although 
the seasons should not be seen here as final triggers of crossing of the 
thrombosis threshold, there may be information available within a specific 
season that could explain a higher chance of developing venous thrombosis. 
In Chapter 3, we describe a consecutive case series of patients with venous 
thrombosis from three different regions; i.e. Italy, The Netherlands and 
Norway in which we study the incidence of venous thrombosis within the 
four seasons.  
 
Overweight/Obesity	  
Overweight or obesity is associated with a 2- to 3-fold increased risk of first 
venous thrombosis compared with individuals with a normal weight [21,22]. 
It is not completely understood how obesity predisposes to venous 
thrombosis, but a recent observation provided evidence that it is at least 
partly mediated by factor VIII induced Activated Protein C-resistance [23]. 
In the same study it was shown that the combination of blood group non-O 
with a high body mass index or factor V Leiden led to higher venous 
thrombosis risks than expected when these prothrombotic factors were 
analyzed separately [23]. However, due to small numbers, the authors could 
not sufficiently study the risk of venous thrombosis for the combination of a 
high body mass index with factor V Leiden and blood group non-O in 
subgroups in sufficient detail, like separately for individuals at risk of 
provoked or unprovoked venous thrombosis.  In terms of personalized 
prevention measures, it is of interest to identify high and low-risk groups. 
Hypothetically, these individuals might have such a high thrombosis 
potential, that additional provoking risk factors, such as oral contraception or 
long-haul travel, could easily lead to the crossing of their thrombosis 
threshold. If so, it could be justifiable to target these individuals for future 
preventative thromboprophylaxis decisions.  For this reason, we set out to 
determine whether the presence of factor V Leiden with blood group non-O 
modifies the risk for venous thrombosis in various body mass index strata 
(Chapter 4) and evaluated the presence of gene-environment interactions in 




Protein	  S	  levels	  
Protein S is a vitamin K-dependent plasma glycoprotein that functions as a 
nonenzymatic cofactor of activated protein C in the inactivation of the 
procoagulant factors Va and VIIIa, and plays an important role in regulating 
thrombin generation [24]. Based on antigen levels and Activated Protein C-
cofactor activity, protein S deficiency can be classified as type I (decreased 
levels of both total and free protein S antigen), type II (total and free protein 
S antigen levels within their normal ranges, but decreased Activated Protein 
C-cofactor protein S activity), and type III (decreased levels of free protein S 
antigen levels only) [25]. Most studies that showed that protein S deficiency 
was related with an increased risk for venous thrombosis have been 
performed in thrombophilic families [26,27]. In population-based studies, 
the risk of thrombosis associated with protein S deficiency is less well 
defined. Some studies find an up to 2.5 times increased risk, others find no 
increase at all [28-30]. A difference in risk between subjects with type I and 
type III deficiency, together with variation in the distribution of hereditary 
protein S deficiency among the studied populations may explain this 
discrepancy, although these types were not distinguished in the published 
reports. Nevertheless, the clinical relevance for the individual patient could 
be substantial as individuals with inherited proteins S deficiency seem to 
easily cross the thrombosis threshold for both first venous thrombosis 
(absolute risk of 1.5-2% per year) and recurrent venous thrombosis (annual 
recurrence risk of 6-10%) [26]. In Chapter 5 we therefore set out to 
determine if in a large population-based case-control study (MEGA study) 
low levels of free protein S or total protein S were associated with an 
increased risk of venous thrombosis. The molecular basis for protein S 
deficiency was additionally investigated by analysis of copy number 
variation of PROS1 and sequencing of individuals with the lowest levels of 
protein S in an attempt to explain the different findings in risk estimates 
between families and population studies. 
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Old	  concepts:	  risk	  factors	  for	  recurrent	  
venous	  thrombosis	  
Treatment with oral anticoagulants successfully reduces the risk of recurrent 
venous thrombosis, albeit at the cost of an increased risk of severe or fatal 
bleeding. The optimal duration of anticoagulant treatment therefore depends 
on the balance between risk of recurrent venous thrombosis and risk of 
bleeding. According to the American College of Chest Physicians 2012 
guidelines, primary factors for estimating the risk of recurrence are the 
presence of a reversible provoking risk factor, unprovoked venous thrombosis 
and the presence of active cancer [31]. Yet, only 50% of patients can be 
classified at such low risk of recurrence that anticoagulation can be 
discontinued after 3-6 months (provoked venous thrombosis) or at such high 
risk of recurrence that anticoagulation should be continued for indefinite time 
(active malignancy). For the other 50% of patients prediction of recurrent 
venous thrombosis remains a clinical dilemma [32]. Chapter 6 briefly 
outlines what is currently known about the epidemiology of recurrent venous 
thrombosis, and also focuses in more detail on potential new risk factors for 
venous thrombosis recurrence.  
 
Past	  provoking	  risk	  factors	  
Although it has been recognized that the presence of a transient or reversible 
provoked risk factor at the time of venous thrombosis is associated with a 
decreased risk of recurrence after anticoagulant therapy is stopped [33], a 
substantial number of recurrent events occur without a clear provoking risk 
factor. The challenge therefore is to identify other patient groups that may 
also have a low risk of recurrence and could receive anticoagulants for a 
fixed (short) time. The thrombosis potential model takes into consideration 
that the thrombosis potential will drop sharply after the occurrence of a 
provoked event and that such an individual will not readily cross the 
thrombosis threshold again, consequently leading to a reduced risk for 
recurrence. Considering this model we hypothesized in Chapter 7 that 
patients at risk for recurrent venous thrombosis who had experienced 
transient provoked risk factors previously, yet not developed thrombosis at 
that time, would have a lower risk of recurrence than those whose first 
(provoked or unprovoked) event was not preceded by provoked risk factors. 





Since 1965, an increasing number of abnormalities of coagulation and 
fibrinolysis have been identified as risk factors for venous thrombosis. These 
thrombophilic defects include hereditary deficiencies of antithrombin, 
protein C and protein S, factor V Leiden, prothrombin G20210A, elevated 
levels of factors VIII, and hyperhomocysteinemia [34]. Meanwhile 
thrombophilic alterations can be demonstrated in at least 50% of patients 
with venous thrombosis [34], testing patients with a first venous thrombosis 
for thrombophilia has gained great interest. However, whether patients with 
venous thrombosis should be tested for thrombophilic defects is still a matter 
of debate [35]. Potential advances of testing patients might be the 
opportunity to elucidate the cause of the thrombosis and to track unaffected 
family members. However, there are potential disadvantages of testing for 
thrombophilia. For instance, the negative results of thrombophilia for the 
prediction of a recurrent event does not support wide spread testing [35,36]. 
However, these negative results were mostly obtained in persons with any 
first venous thrombosis. Whether thrombophilia has predictive value for 
recurrence in persons who had a first unprovoked event is less well studied. 
In order to assess these issues, we performed a prospective cohort study, 
described in Chapter 9 to assess the risk of recurrence in patients with 
provoked and unprovoked first venous thrombosis, related to the presence or 
absence of thrombophilia.  
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Table 1. Risk factors for first venous thrombosis
Relative Reference with Discussed
risk* risk estimates† in this thesis
Genetic
- Antithrombin deficiency 15-20 Heijboer et al, 1990; Simioni et al, 1999 No
- Protein C deficiency 15-20 Heijboer et al, 1990; Simioni et al, 1999 No
- Protein S type I deficiency 15-20 Heijboer et al, 1990; Simioni et al, 1999 Yes, chapter 5
- Factor V Leiden 5-7 Rosendaal et al, 1995 Yes, chapters 1,4
- Prothrombin G20210A 2-3 Poort et al, 1996 Yes, chapters 1,4
- Non-O blood group 1.5-1.8 Jick et al, 1969 Yes, chapters 1,4
- Factor XIII val34leu 1.2-1.5 Franco et al, 1999 No
- Recently discovered SNPs 1.1-1.4 Smith et al, 2007; Bezemer et al, 2008 No
Acquired 
- Increasing age 1-∞ Naess et al, 2007 Yes, chapter 6
- Malignancy 7-20 Blom et al, 2005 Yes, chapters 4,6,7
- Lupus anticoagulant 3-10 Ginsberg et al, 1995 No
- Systemic lupus erythematosus 3-8 Brouwer et al, 2004 No
- Inflammatory bowel disease 3-4 Grainge et al, 2010 No
- Hyperthyroid disease 1.5-3 Cannegieter et al, 2009 No
- HIV 3-10 Sullivan et al, 2000 No
- Nephrotic syndrome 3-10 Mahmoodi et al, 2008b No
- Renal transplant recipients 3-8 Poli et al, 2006 No
- Chronic kidney disease 1.3-1.7 Wattanakit et al, 2008 No
- Microalbuminuria 1.5-2.5 Mahmoodi et al, 2009 No
- Overweight and obesity 2-3 Kakkar et al, 1970; Pomp et al, 2007 Yes, chapters 4,5,6
Environmental
- Surgery, trauma, immobilization 5-50 Nicolaides et al, 1973 Yes, chapter 7
- Pregnancy and puerperium 3-5 Kierkegaard, 1983; McColl et al, 1997 Yes, chapters 4,7
- Oral contraceptives 4-7 Sartwell et al, 1969 Yes, chapters 4,7
- Hormone replacement therapy 2-5 Grodstein et al, 1996 Yes, chapters 4,7
- Air travel 1.5-3 Sarvesvaran, 1986; Cannegieter et al, 2006 No
- Transient infectious disease 1.0-3.0 Smeeth et al, 2006 Yes, chapters 1,8
Mixed 
- Low (free) protein S levels 5-10 Faioni et al, 1997 Yes, chapter 5
- High factor VIII 3-5 Koster et al, 1995 Yes, chapter 8
- APC-resistance 3-5 Koster et al 1993 Yes, chapter 4
- High factor IX 2-3 van Hylckama Vlieg et al, 2000 No
- High factor XI 1.5-2.5 Meijers et al, 2000 No
- High TAFI 1.5-2.5 van Tilburg et al, 2000 No
- Hyperhomocysteinaemia 1.5-2.5 Den Heijer et al, 1996 No
- Hypofibrinolysis 1.5-2.5 Lisman et al, 2005 No
- Enhanced thrombin generation 1.5-2.5 Brummel-Ziedins et al, 2005 No
Not well established
- Air pollution 1.1-2.0 Baccarelli et al, 2009 Yes, chapter 7
- High CRP 1.2-1.8 Quist-Paulsen et al, 2009 No
- Abnormal interleukin levels 1.0-2.5 van Aken et al, 2002 No
- Seasonal variance 1.0-2.5 Bounameaux et al, 1996 Yes, chapter 3
- Hypertension 0.7-2.0 Ageno et al, 2008 No
- Diabetes mellitus 0.7-2.0 Tsai et al, 2002; Heit et al, 2009 No
- Male sex 0.8-1.5 Naess et al, 2007; Andreou et al, 2008 Yes, chapter 6,7
- Smoking 0.8-1.5 Pomp et al, 2008 No
- Dyslipidemia 0.8-1.5 Glynn & Rosner, 2005 No
* Risk for first venous thrombosis compared to the general population.
† We have attempted to give a reference to the first paper from which a risk estimate could be inferred. 
In some cases, these were such early papers with unstable estimates, that we also included 
references to more recent papers with precise estimates.
SNPs denote single nucleotide polymorphisms; TAFI, thrombin activatable fibrinolysis inhibitor.
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Figure 1. A way to think about causality for venous thrombosis: the thrombosis 
potential model 
individual with factor V Leiden












          Age (years)
The figure shows the thrombosis potential of an individual with factor V Leiden and 
of an individual with blood group non-O. Both experience a short period of immobilisation at 
a similar age. This leads to an excess of the thrombosis threshold level in the individual 
with factor V Leiden which consequently leads to deep vein thrombosis, while the individual
with blood group non-O does not develop thrombosis.
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A recent prospective population-based cohort study showed that elevated C-
reactive protein (CRP) levels were associated with an increased risk of venous 
thrombosis [1]. Interestingly, it was shown that this risk was highest when 
CRP levels were elevated during the period directly prior to the onset of 
venous thrombosis. This finding supports the hypothesis that the coagulation 
system can be stimulated by transient inflammatory processes [2], which has 
also been suggested by experimental studies [3]. Two retrospective cohort 
studies showed that patients with pneumonia had a 2- to 3-fold elevated risk of 
acute venous thrombosis [4,5]. However, there is uncertainty on the extent to 
which this risk is causal. Pneumonia is often accompanied by transient periods 
of immobilization or hospitalization leading to venous stasis that could explain 
the association. Alternatively, life style could confound the association, when 
habits such as smoking and physical activity are related to both risk of 
pneumonia and risk of venous thrombosis. Furthermore, it is uncertain 
whether the degree to which the risk is increased justifies thromboprophylaxis 
in these patients. For this discussion it may be important to have knowledge on 
risk groups in whom the risk is additionally increased.  
To study this, we set out to determine if pneumonia was associated with an 
increased risk of venous thrombosis in a large population-based case-control 
study (MEGA study), and whether this risk was influenced by underlying 
relative immobility or unhealthy lifestyle factors. Furthermore, we assessed 
gene-environment interactions, i.e., the combined effect between pneumonia 
and prothrombotic genes that may be clinically relevant for targeted 
thromboprophylaxis. 
The MEGA study is a population-based case-control study that has been 
described in detail elsewhere [6]. Approval for this study was obtained from 
the Medical Ethics Committee of the Leiden University Medical Center, and 
all participants provided written informed consent according to the Helsinki 
Declaration. Participants were aged 18 to 70 years. 4956 consecutive 
patients with deep-vein thrombosis or pulmonary embolism (both 
objectively confirmed with radiologic techniques) were enrolled, together 
with 6297 age- and sex-matched controls. Participants were asked to fill in a 
standardized questionnaire within a few weeks after inclusion in the study. 
The questionnaire provided information on weight, height, smoking status, 
physical activity, and risk factors for venous thrombosis, including recent 
(within three months prior to the index date) trauma, plaster cast use, 
surgery, pregnancy/puerperium, or immobilization (bedridden at home for at 
least 4 days, hospitalization), > 4 hours travelling by air, train, bus, or car in 
the 8 weeks before the index date, estrogen/progestagen use (oral 
contraceptives or hormonal replacement therapy) at time of the index date, 
and diagnosis of malignancy within five years before the index date. In 
addition, questions were asked about pneumonia in the year before the index 
date. All answers were self-reported and the exact dates of these events were 
not available. Body mass index (BMI) was calculated by dividing weight 
(kg) by height squared (m2).  Smokers were divided in current, previous, and 
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never smokers. When the difference between the age at index date and the 
age of smoking cessation was 1 year or less, the person was considered a 
current smoker. Participants who participated in sports activities at least once 
a week were considered to be physically active [9]. The index date was the 
date of the thrombotic event for patients and their partners and the date of 
filling in the questionnaire for the random controls. In addition, participants 
provided a blood or buccal swab sample for DNA. Common genetic risk 
factors were assessed, i.e., the factor V Leiden mutation and prothrombin 
G20210A. These were determined by polymerase chain reactions using the 
TaqMan assay. Technicians were blinded to whether the samples came from 
patients or controls. For the present analysis, questionnaire data on 
pneumonia were available from 4281 patients and 5752 controls.  
Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated 
as estimates of the relative risk, and were adjusted for age and sex by logistic 
regression methods to take the matching into account. Subgroup analysis 
involved stratification of patients with deep vein thrombosis of the leg only, or 
with pulmonary embolism +/- deep vein thrombosis. We adjusted our findings 
for classical venous thrombosis risk factors (defined as trauma, surgery, > 4 
hours travelling, malignancy and, for women, pregnancy/puerperium or the 
use of hormone therapy) [6] and for unhealthy life style factors 
(overweight/obesity, smoking habit and physical activity) with logistic 
regression methods to determine whether the associations could be explained 
by confounding through these factors. To quantify the effect of immobilization 
as a mediator of the risk of venous thrombosis in pneumonia participants 
(pneumonia leads to immobilization which in its turn leads to venous 
thrombosis), we further adjusted the analysis for immobilization. The 
combined effect of prothrombotic genes and pneumonia was evaluated 
through a stratification analysis (4 strata with the different combinations of 
presence and absence of either factor). All statistical analyses were performed 
with SPSS for Windows, release 17.0 (SPSS Inc, Chicago, IL).  
Our study included 2887 patients with deep-vein thrombosis only and 2069 
patients with pulmonary embolism +/- deep-vein thrombosis. Median age 
(interquartile range) was 50 years (39-59) for patients and 48 years (37-57) 
for controls. 2274 (46%) of patients were male and 2914 (46%) of controls 
were male. Patients were slightly older than control subjects (median 50 vs. 
48 years), they were more often overweight/obese (63% vs. 51%), smoked 
more often (66% vs. 60%) and were more often physically inactive (69% vs. 
62%). Furthermore, classical venous thrombosis risk factors were more often 
present in patients than in control subjects (72% vs. 40%). 891 Patients 
(18%) were hospitalized in the previous three months before the index date, 
as compared with 176  (3%) controls. 
A period of pneumonia in the year before the thrombotic event was present 
in 7.2% (N=307) in patients and in 1.5% (N=87) in controls (Table 1). 
Participants with prior pneumonia were 5 times more likely to have venous 
Chapter 2 
 26 
thrombosis (odds ratio 5.0; 95% CI, 3.9-6.3), than participants without 
pneumonia. This risk was higher when pulmonary embolism was considered 
(odds ratio 7.9; 95% CI, 6.1-10.3, for pulmonary embolism plus or minus 
deep vein thrombosis and [8.1; 95% CI, 6.2-10.6 for pulmonary embolism 
only] than when deep vein thrombosis only was considered ([odds ratio 3.0; 
95% CI, 2.2-4.0]). To investigate whether the study results in Table 1 could 
be due to the presence of confounding, we adjusted our findings for age, sex, 
classical risk factors for venous thrombosis and healthy lifestyle, which led 
to minimal attenuation of the effect estimates (Table 2). Additional 
adjustment for immobilization (as a mediator) led to a slight decrease in 
relative risk for venous thrombosis with an odds ratio of 3.8 (95% CI, 2.9-
5.1). When patients with deep-vein thrombosis only were compared with 
controls, this odds ratio was 1.9 (95% CI, 1.3-2.7).  Further exclusion of 
vitamin K antagonist users at time of the index date (11 patients and 34 
controls) did not affect the risk estimates.  
Next, we analyzed whether a combined effect of prothrombotic genes and 
pneumonia would lead to an increased venous thrombosis risk (Table 3). 
Among factor V Leiden carriers without pneumonia the risk of venous 
thrombosis was 3.4-fold (95% CI, 2.9-4.0) increased. Participants with 
pneumonia who were non-carriers of factor V Leiden had a 5.5-fold (95% CI, 
4.1-7.3) increased risk, while those who had factor V Leiden and pneumonia 
had a 17.8-fold (95% CI, 5.5-57.7) increased risk compared to non-carriers 
without pneumonia. A similar joint effect was observed for prothrombin 
G20210A and pneumonia on venous thrombosis risk (Table 3).  
In this large population based case-control study, recent pneumonia was a 
moderate to strong risk factor for venous thrombosis. Participants who had 
pneumonia had a 5-fold increased risk of venous thrombosis within one year. 
Pneumonia resulted in a more pronounced relative risk of pulmonary 
embolism than of deep vein thrombosis. This latter finding may reflect local 
inflammatory effects in the lungs [7], but it may also be due to 
misclassification, which is possible as signs and symptoms of pneumonia can 
be similar to pulmonary embolism. To determine whether the associations 
could be explained by classical venous thrombosis risk factors or unhealthy 
life style, we adjusted for these factors. The presence of classical venous 
thrombosis risk factors did not affect our outcomes, nor did adjustment for 
unhealthy lifestyle factors. These results provide evidence that the association 
between infectious or inflammatory disease and venous thrombosis cannot be 
explained by unhealthy life style. Immobilization, however, attenuated the 
effect from 5.0 to 3.8, indicating that immobilization could play a role in the 
mechanism of pneumonia leading to venous thrombosis. Although the relation 
that remained could possibly be explained by residual confounding, as 
unhealthy life style could not be measured in great detail [8,9], it is not likely 
that we missed a confounder that can fully explain the remaining 4-fold 
increased risk. Alternatively, the association could point towards a causal 
association between pneumonia and venous thrombosis. Inflammation 
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influences endothelial function through protease-activated receptors (PARs) 
signaling [10]. Our finding that pneumonia is associated with venous 
thrombosis is biologically plausible if pneumonia increases venous thrombosis 
risk by PAR signaling leading to a procoagulant response [11], and ultimately, 
to venous thrombosis. Other aspects that are in favor for the supposed causal 
association between pneumonia and venous thrombosis include the strength of 
the association, consistency with studies that also analyzed the association 
[2,4,5], and a temporal relationship wherein pneumonia occurred before the 
event took place.  
From Table 3 it can be noted that the ‘factor V Leiden paradox’ [12] is again 
present in patients with factor V Leiden without pneumonia: in these patients 
the risk of deep-vein thrombosis is higher than that of pulmonary embolism. 
For patients with just pneumonia in the absence of factor V Leiden the 
opposite is the case, i.e. risk of pulmonary embolism is clearly higher than that 
of deep-vein thrombosis. Interestingly, in patients who have both, both odds 
ratios are first of all much higher and secondly, the factor V Leiden paradox 
does not play a role anymore. Apparently the effect of the pneumonia is 
stronger with a stronger effect on pulmonary embolism than on deep vein 
thrombosis. The clear joint effects for both factor V Leiden and prothrombin 
G20210A in combination with pneumonia on venous thrombosis risk (18 to 
32-fold increased risks compared to non factor V Leiden/prothrombin 
G20210A carriers without pneumonia) was high enough to deliberate on the 
need for a different thromboprophylactic approach in these subjects.  Of note, 
such a strategy should be supported by clinical trials before a strong clinical 
recommendation on whether persons with abovementioned thrombophilia 
should or should not receive thromboprophylaxis at time of pneumonia. 
The strengths of this study include the large patient sample, the detailed 
information about venous thrombosis risk factors in both patients and 
controls, and the combination with data on prothrombotic genes. A 
limitation of this study is that pneumonia was assessed via self-report in our 
study. However, we expect that both patients and control persons reported 
pneumonia without much misclassification, since pneumonia is a major 
disease with a large impact. Another limitation is that we could not study the 
exact temporal relationship between pneumonia and venous thrombosis risk 
as our questionnaire did not provide the exact dates of pneumonia, but only 
whether these diseases occurred in the year before the index date. This may 
have diluted our risk estimates.  
In summary, in this large population based case-control study pneumonia 
substantially increased the risk of venous thrombosis. This association could 
only partially be explained by a concurrent period of immobilization or life 
style. The 18 to 32-fold increased risk of venous thrombosis in participants 
with pneumonia and factor V Leiden or prothrombin G20210A should be 
considered when people known to have these prothrombotic genes present 
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Circannual variability of venous thrombosis has been reported since 1939, 
but there is no definitive determination of whether it really exists. Although 
a recent meta-analysis on this topic, including 35 000 patients with venous 
thrombosis, has recently been published [1], and showed a similar existence 
of a seasonal variability in venous thrombosis as for arterial cardiovascular 
disease [2-6], there are some issues that preclude whether this meta-analysis 
found a true association between seasonal variability in the incidence of 
venous thrombosis. First, the meta-analysis did not rule out the possibility of 
publication bias. Second, the meta-analysis did not include a large 
observational study of seven million individuals from the United States that 
failed to find a seasonal variability on incidence of (ICD-9-CM diagnosed) 
venous thrombosis [7]. Third, the meta-analysis was dominated by one study 
(n=20.000, 70% of the included cases) that found a strong effect on the 
incidence of venous thrombosis (lowest in spring, highest in winter) [8]. 
Therefore, it could be argued that the inclusion of the other studies in the 
meta-analysis added very little, and that the meta-analysis showed no more 
than the one large study published by Gallerani et al [8].  
Nevertheless, the reported association between the seasons and the incidence 
of venous thrombosis is supported by studies showing that cold temperature 
was associated with increased levels of coagulation factors [9,10]. Also, 
transient infections (like pneumonia or influenza) are more common in the 
colder seasons of temperate climates, which may also increase the risk of 
venous thrombosis [11]. Furthermore, air pollutants are more common in 
Winter months as compared to Spring, especially in larger city areas [12]. 
Interestingly, some studies [13], but not all [14], suggest that air pollution 
increases the risk of venous thrombosis. Finally, vitamin D, synthesized in 
the skin after sun exposure, has been related to fibrinolytic and procoagulant 
activity [15,16]. Therefore sun exposure during the Summer months may 
consequently lower the risk of thrombotic events.  
We had the opportunity to study circannual variability of venous thrombosis in 
three regions (i.e. Milan/ Italy, Leiden/the Netherlands and Tromsø/Norway). 
These three regions have a similar climate, and are similarly situated around 
sea level, but differ in the annual temperature, which is highest in Milan (mean 
13.5°C)  (http://www.climatetemp.info/italy/milan.html) lower in Leiden 
(mean 9.6°C) (http://www.climatetemp.info/netherlands/) and lowest in 
Tromsø (mean 2.9°C) (http://www.climatetemp.info/norway/tromso.html). 
Regions are demographically comparable in terms of ageing and health status 
(http://en.istat.it/, www.cbs.nl and www.ssb.no), but differ in terms of air 
pollution (high in Milan and Leiden, lower in Tromsø) [17]. They also differ 
in terms of sunlight (with the irregular fall in the hours of sunlight and the 
steady fall in the length of daylight over the seasons that can be extreme in 
Tromsø, and which is approximately similar in Milan as compared to Leiden). 
Therefore, regions are matched on demographic and climate variables, but 
differ in terms of temperature, sunlight and air pollution.   
This study was performed in the Multiple Environmental and Genetic 
Assessment (MEGA) study (from Leiden), the Tromsø study (from Tromsø) 
Chapter 3 
 36 
and in the Lombardy region (from Milan). The MEGA study is a large 
population-based case-control study. Between March 1, 1999 and August 31, 
2004, all consecutive patients between the age of 18 and 70 with a first deep-
vein thrombosis (DVT) of the leg or pulmonary embolism (PE) have been 
identified at six regional anticoagulation clinics in the Netherlands [18]. Four 
thousand nine hundred and fifty-six patients were included in whom the 
diagnosis of incident venous thrombosis was confirmed by objective methods.  
In the Tromsø study, participants were recruited from the fourth survey of 
the Tromsø study conducted in 1994-95, a single-center, prospective, 
population based study, with repeated health surveys of inhabitants in the 
city of Tromsø, Norway [15]. All inhabitants aged 25 years or older were 
invited, and 27158 participated (77% of the population invited). Incident 
venous thrombosis (N=661) events among the study participants were 
recorded from the date of enrollment through the end of follow- up, 
September 1, 2007.  
The study from Milan is a population based case-control study where 2081 
patients had been diagnosed between 21 December 1993 through 20 
December 2010 as having incident DVT or PE [16]. Patients were referred to 
the Thrombosis Center, Fondazione IRCCS Ca’ Granda - Ospedale 
Maggiore Policlinico, Milan, Italy, for a thrombophilia screening. All three 
studies were approved by the regional committee for research ethics, and all 
participants gave their informed, written consent.  
In the MEGA study (Leiden), we evaluated in 4 completed seasonal cycles 
(21 December 2000 to 20 December 2003), if consecutive cases with venous 
thrombosis (N=2666) had more events in winter compared to other seasons. 
Similarly, in the Tromsø study, we evaluated the frequency of venous events 
(N=596) in 12 completed seasonal cycles (21 March1994 to 20 March 
2006). In Milan, the same figure was evaluated in 17 completed seasonal 
cycles (21 December 1993 to 20 December 2010). Two thousand two 
hundred and ninety patients from MEGA, 65 patients of Tromsø and no 
patient from Milan were excluded in order to let the cycles of seasons be 
complete. We labeled Winter as the period of time between December 21 - 
March 20; Spring March 21 - June 20; Summer June 21 - September 20; and 
Autumn September 21 - December 20.    
Clinical characteristics of the Leiden, Tromsø, and the study from Milan are 
provided in Table 1. Approximately half of the patients were men, and the 
mean age at time of thrombosis was 49 years (interquartile range 39-61). In 
all three studies, the prevalence of venous thrombosis was lowest in spring 
as compared with the other seasons (absolute risk difference - 2.3%, 95% CI, 
-4.0 to -0.7) (Figure 1). The absolute risk difference (taking Spring as a 
reference group) was -2.6% (95% CI, -4.3 to -1.0) to Winter, -2.2% (95% CI 
-3.8 to -0.6) to Summer and -2.2% (95% CI, -3.8 to -0.5) to Autumn, 
respectively. When unprovoked events, or incident PE, or men only were 
analyzed separately, a similar pattern was observed, that is: a lower 
prevalence of thrombosis in Spring than in the other seasons (Table 1).  
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In this study we observed a difference in the distribution of venous 
thrombosis over the seasons in all three studies, wherein the prevalence was 
lowest in Spring, and somewhat similar over the other seasons. Because our 
numbers were fairly large (n=5343), the absolute difference of venous 
thrombosis between Spring and the other seasons was statistically 
significant. However, the clinical relevance of a 2% seasonal variation in 
incidence of venous thrombosis is questionable. Still, these results were 
consistent within all three studies. Therefore, our finding (lower prevalence 
of venous thrombosis in Spring) at least provides a suggestion that the 
association that we found is true. But even if the association is true, a causal 
interpretation of this finding is hard to provide. To proof causality, one 
would like to know an intervention strategy [19], and the intervention 
“Spring” seems too ambiguous to use as an intervention tool. Nevertheless, 
some things can be inferred from our results. First, our findings cannot be 
explained by a sole linear increase of temperature, because the prevalence of 
venous thrombosis was higher in the hottest season (Summer) as compared 
to Spring in all three studies. Second, transient infections are also not very 
likely to explain our results. Although transient infections (pneumonia, 
influenza) are more common in the colder seasons of temperate climates 
[20], there was a small difference in venous thrombosis prevalence between 
the Summer season and Winter/Autumn in all three studies. Third, our 
results are also probably not explained by sunlight exposure. Although in all 
three regions, sunlight is mostly present from about 21 May to 21 July, 
sunshine hours are extreme in Tromsø (midnight sun around those dates), 
while the prevalence of venous thrombosis in Tromsø was only slightly 
different over the colder seasons compared to Spring and Summer, 
especially when compared to the Leiden or Milan findings. A fourth 
explanation may be air pollution, which is lowest in Spring and highest in 
Autumn/Winter and Summer months in the Milan region [8]. However, in 
Norway air pollution is rather high during Spring (explained probably by dry 
asphalt and studded tyres) [19].  Still, in Tromsø the prevalence of venous 
thrombosis was also lowest in Spring. Another explanation for seasonal 
variations of venous thrombosis is a referral bias (e.g. with more patients 
referred to diagnostic centers during the warm season due to more edema in 
that season). We only included confirmed venous thrombotic events and 
therefore we cannot rule out that this is the reason for an excess of patients in 
Summer. However, in a previous study, the distribution of suspected events 
has been scrutinized and shown not to be influenced by the season or 
calendar month [20].  
In summary, in our study the risk of venous thrombosis was different 
between the seasons, with the lowest prevalence noted in Spring. The 
absolute difference in risk in Spring as compared with the other seasons was 
small (2%) is without any clinical relevance. This difference may well have 
to do with the weather, although other causes cannot be ruled out. 
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Table 1. Clinical characteristics by seasons
Total Winter Spring Summer Autumn
Leiden study
Any venous thrombosis 2666 (100) 683 (25.6) 616 (23.1) 666 (25.0) 701 (26.3)
Male 1219 (46) 334 (49) 269 (44) 294 (44) 322 (46)
Age at enrollment 49 (39-59) 49 (39-59) 50 (41-60) 48 (38-58) 49 (38-60)
DVT only 1567 (59) 418 (61) 361 (59) 391 (59) 397 (57)
PE +/- DVT 1099 (41) 265 (39) 255 (41) 275 (41) 304 (43)
Provoked* 1595 (62) 471 (72) 460 (77) 468 (73) 196 (29)
Unprovoked* 989 (38) 186 (28) 140 (23) 173 (26) 490 (71)
Tromsø study
Any venous thrombosis 596 (100) 155 (26.0) 144 (24.2) 147 (24.7) 150 (25.2)
Male 290 (49) 71 (46) 73 (51) 78 (53) 68 (45)
Age at enrollment 62 (51-77) 62 (51-78) 66 (55-79) 60 (48-75) 60 (50-75)
DVT only 388 (65) 92 (59) 102 (71) 100 (67) 94 (64)
PE +/- DVT 208 (35) 63 (41) 42 (29) 50 (33) 53 (36)
Provoked 329 (55) 100 (65) 96 (67) 88 (60) 45 (30)
Unprovoked 267 (45) 55 (35) 48 (33) 59 (40) 105 (70)
Milan study
Any venous thrombosis 2081 (100) 545 (26.2) 482 (23.2) 548 (26.3) 506 (24.3)
Male 986 (47) 265 (49) 227 (47) 265 (48) 229 (45)
Age at enrollment 45 (31-58) 46 (32-60) 45 (31-58) 44 (31-56) 45 (31-59)
DVT only 1675 (80) 437 (80) 397 (82) 435 (79) 406 (80)
PE +/- DVT 406 (20) 108 (20) 85 (18) 113 (21) 100 (20)
Provoked 1383 (67) 348 (36) 328 (32) 374 (68) 333 (66)
Unprovoked 698 (33) 197 (64) 154 (68) 174 (32) 173 (34)
Three studies combined
Any venous thrombosis 5343 (100) 1383 (25.9) 1242 (23.2) 1361 (25.5) 1357 (25.4)
Male 2495 (47) 670 (48) 569 (46) 637 (47) 619 (46)
Age at enrollment 49 (36-61) 49 (36-61) 50 (38-61) 48 (35-59) 48 (36-61)
DVT only 3630 (67) 947 (69) 860 (69) 923 (68) 900 (66)
PE +/- DVT 1713 (32) 436 (31) 382 (31) 438 (32) 457 (34)
Provoked 3661 (70) 919 (68) 884 (72) 930 (70) 928 (69)
Unprovoked 1600 (30) 438 (32) 342 (28) 406 (30) 414 (31)
* Unknown for 82 cases.
Continous variables denoted as mean (IQR), categorical data as count (%). 
DVT, deep vein thrombosis; PE, pulmonary embolism.
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Figure 1. Seasonal differences in the prevalence of first venous thrombosis in Leiden, 
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Background: Overweight/obesity has a substantial effect on the occurrence 
of venous thrombosis (VT). Blood group non-O has a high prevalence in 
Western populations and factor (F)V Leiden mutation could be present in 
5% of Caucasians. These frequent prothrombotic risk factors will have a 
considerable impact on the incidence of VT, especially when combined.  
Objectives: We investigated if FV Leiden with blood group non-O modifies 
VT risk in individuals with different body mass index (BMI) strata in a case-
control study (n=11253).  
Results: We observed a progressively increasing risk of VT for higher BMI 
with an odds ratio of 1.9 (95%CI, 1.6-2.3) for those in the upper tertile 
(BMI>26.7 kg/m2), as compared with the first BMI tertile (BMI< 23.5 
kg/m2, blood group O, and no FV Leiden (reference group). The addition of 
FV Leiden and blood group non-O to the model increased the risk in all BMI 
tertiles; odds ratios were 3.8 (95%CI, 3.2-4.6) in the third BMI tertile of 
individuals with blood group non-O, and 5.4 (95%CI, 3.5-8.5) in the third 
BMI tertile of individuals with FV Leiden, respectively. When both FV 
Leiden and blood group non-O were present, odds ratios were 9.1 (95%CI, 
5.9-14.0) in the first BMI tertile, 9.4 (95%CI, 6.6-13.5) in the second BMI 
tertile, and 12.5 (95%CI, 8.9-17.6) in the third BMI tertile.  
Conclusion: Individuals with a high BMI, blood group non-O and/or FV 
Leiden are at high VT risk. The high VT risks in some subgroups may justify 




Obesity and overweight have considerable effects on the occurrence of a 
variety of disorders such as coronary artery disease, hypertension, type II 
diabetes and venous thrombosis (VT) [1,2]. A high and still increasing 
prevalence of obesity in developed countries (prevalence of 20-25% in 
Western populations) leads to substantial impact on disease occurrence. 
Several studies have shown an association between blood group non-O and 
factor (F)V Leiden with a 23-fold increase in risk for VT [3]. The prevalence 
of blood group non-O is about 50% in Western populations and FV Leiden is 
present in 5% of Caucasians [4,5]. These frequent prothrombotic risk factors 
will have a considerable impact on the overall incidence of VT, especially 
since the frequent combined presence of these mutations has a positive joint 
effect on venous thrombotic risk [4]. We previously reported that the 
increased risk of VT in individuals with a high body mass index (BMI) is 
mediated by FVIII induced APC-resistance, and that having blood group 
non-O or factor V Leiden plus a high BMI leads to higher VT risks than 
expected when these prothrombotic factors are analyzed separately [6]. 
However, due to small numbers we were not able to study the risk of VT for 
the combination of a high BMI with FV Leiden and blood group non-O, or 
to study whether these effects differ for example for provoked or 
unprovoked VT.  
For this reason, we set out to determine whether the presence of FV Leiden 
alone or with blood group non-O modifies the risk of VT in various BMI 
strata. This study was performed in a different and larger population (i.e., 
Multiple Environmental and Genetic Assessment of risk factors for VT 
[MEGA] study) [5,7], than previously reported [6]. In addition, we evaluated 
the presence of gene-environment effect modification in specific subgroups. 
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The MEGA study is a population-based case-control study that has been 
described in detail elsewhere [5,7]. Participants were aged 18-70 years. 4956 
Consecutive patients with deep-vein thrombosis or pulmonary embolism 
were enrolled, together with 6297 age- and sex-matched controls. A 
questionnaire was filled in to assess VT risk factors. The questionnaires 
included items on surgery, injury, plaster cast, immobilization, malignancies, 
pregnancy, use of oral contraceptives, and hormone replacement therapy. 
BMI was calculated by dividing body weight (kg) by squared height (m2). 
Overweight was defined as a BMI between 25-30 kg/m2 and obesity as BMI 
>  30 kg/m2. In addition, participants provided a blood or buccal swab 
sample for DNA. FV Leiden and ABO-blood group were determined by 
polymerase chain reactions using the TaqMan assay. Technicians were 
blinded to whether the samples came from patients or controls. For the 
present analysis, data on BMI, blood group and factor V Leiden was 
available in 4062 patients and 4659 controls.  
Odds ratios with 95% confidence intervals (95%CIs) for the risk of BMI 
tertiles (obtained from the control group) on VT were calculated by using 
logistic regression models, and were adjusted for age and sex. The combined 
effect of BMI, factor V Leiden, blood group non-O and immobility (defined 
as bedridden for more than 4 days, surgery, or hospitalization within 3 
months prior to the index date) were evaluated by means of stratification. 
Subgroup analyses involved stratification by VT type (provoked or 
unprovoked event), VT location (deep-vein thrombosis or pulmonary 
embolism), and sex. For a transparent presentation of effect modification, we 
report the separate effect of each exposure as well as the joint effect 
compared to the unexposed group as a joint reference category to permit 
evaluation of interaction on both an additive and multiplicative scale [8]. 
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RESULTS	  AND	  DISCUSSION	  
Our study included 2363 patients with deep-vein thrombosis only, and 1699 
patients with pulmonary embolism with or without a diagnosed deep-vein 
thrombosis. Median age (interquartile range) was 50 years (39-59) for 
patients and 49 years (39-58) for controls. Prevalence of FV Leiden and 
blood group non-O in patients was 16% (n=651) and 72% (n=2907), 
respectively. In controls, these prevalences were 5% (n=243) and 54% 
(n=2513), respectively. Patients were more often overweight (43% vs 37% 
in controls) or obese (21% vs 14%).  
Table 1 shows the combined effects of ABO blood group and FV Leiden 
within increasing BMI categories on the risk of VT. A progressive increase 
in BMI was associated with an increased risk for VT, odds ratios 1.1 
(95%CI, 0.9-1.3) for those with a BMI in the median tertile, and 1.9 (95%CI, 
1.6-2.3) for those in the upper tertile, as compared with participants in the 
first BMI tertile, blood group O, and no factor V Leiden (i.e. the reference 
group). The addition of factor V Leiden and blood group non-O increased 
the risk in all BMI tertiles; odds ratios for VT were 3.8 (95%CI, 3.2-4.6) in 
the third BMI tertile of participants with blood group non-O, and 5.4 
(95%CI, 3.5-8.5) in the third BMI tertile of participants with factor V 
Leiden, respectively. When both factor V Leiden and blood group non-O 
were present, odds ratios for VT were 9.1 (95%CI, 5.9-14.0) in the first BMI 
tertile, 9.4 (95%CI, 6.6-13.5) in the second BMI tertile, and 12.5 (95%CI, 
8.9-17.6) in the third BMI tertile as compared with the reference group. 
Subgroup analyses, that involved stratification by VT location (i.e. deep-vein 
thrombosis or pulmonary embolism), sex, and presence or absence of 
acquired VT risk factors, maintained positive joint effects of BMI with blood 
group non-O and FV Leiden on VT risk, with the exception for pulmonary 
embolism. Effect modification on at least the additive scale between the risk 
factors involved was observed for most groups. For instance, if blood group 
non-O, and FV Leiden were combined in those with a BMI in the lowest 
tertile, there was effect modification on the multiplicative scale 
(1*2.1*3.1<9.1). There was also effect modification on the additive scale of 
blood group non-O with FV Leiden and BMI in the upper tertile 
(1.9+3.8+5.4-1<12.5). The only group where effect modification was not 
observed was in patients with PE. For the latter, addition of several risk 
factors increased the risk of PE without synergy between these factors. 
We next focused on participants who were exposed to hormone use 
(N=1869), recent travel (n=1452), or immobility (n=1613) (Table 2). Again, 
a dose-response relationship was observed when BMI level increased, with 
an effect for blood group non-O. Participants who were FV Leiden and 
blood group non-O carrier appeared to be at highest risk of VT, independent 
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of BMI, although no longer in a dose-response fashion. Similar results as 
shown in Table 1 and 2 were observed when exposure categories were based 
on WHO classification for overweight/obesity (Tables 3 and 4).   
This study shows that individuals with high BMI, blood group non-O and/or 
FV Leiden are at high VT risk. This confirms the results from our previous 
study [6]. In addition, we showed that the risk increased with the degree of 
obesity and was also increased for unprovoked or provoked VT, for deep-
vein thrombosis and in men or women. We observed little effect of FV 
Leiden on the risk of pulmonary embolism, (also known as the FV Leiden 
paradox) when combined with increasing BMI and/or blood group non-O 
[9,10]. This results adds credence to the hypothesis that APC resistance 
(present in FV Leiden carriers and in individuals with high BMI) [6,11], 
preferentially affects the risk of deep-vein thrombosis and not of pulmonary 
embolism. Furthermore, we found that the combination of high BMI, and 
blood group non-O in non-FV Leiden carriers increased the risk of VT in a 
dose-response fashion in individuals who were exposed to oral 
contraceptives/hormone replacement therapy (odds ratios up to 10-fold 
increased), recent travel (odds ratios up to 11-fold increased), or immobility 
(odds ratios more than 3.5-fold increased).  
Apart from factor VIII induced APC resistance, another factor that could 
explain our observed increased risk estimates is the presence of microparticles. 
Recent evidence points towards microparticles as a potential promoter of a 
hypercoagulable state both in obese individuals, and in FV Leiden carriers 
[12,13]. Interestingly, microparticle activity is reduced in obese individuals 
after weight loss [14]. Therefore, our study, combined with other studies that 
looked into the etiological aspects of hypercoagulability in obesity [1,4,6,12-
14], suggests that weight loss, especially in obese individuals with FV Leiden, 
could contribute to a decrease in risk of venous thrombosis.   
A limitation of our study is that we cannot directly estimate absolute risk 
estimates from case-control data, which hampers clinical decision making 
with respect to thromboprophylaxis. As in persons with immobility the 
absolute risk of VT is estimated to be as high as 3.5% within three months 
after immobilization [15], while thromboprophylaxis with anticoagulant 
drugs reduces this risk with approximately 60% [16], the number needed to 
treat would be 13-20 in this group of individuals (i.e. immobilized 
individuals with a high BMI, blood group non-O and/or factor V Leiden). 
Because the absolute risk of VT in oral contraceptive users (estimated 6 per 
10.000 per year) [17], or recent travel (estimated 1 per 4500 passengers) 
[18], is much lower, a 10 or 11-fold increased risk probably does not justify 
screening for blood group non-O in overweight/obese persons willing to 
travel or take oral contraceptives. It is difficult at this stage to propose a 
balance of benefits and risks for the combination of factor V Leiden with 
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blood group non-O in overweight/obese women who use hormones or 
individuals who travel (which revealed 15 to 45-fold increased risks of VT). 
Although it might be tempting to screen, such an undertaking would likely 
not be cost-effective since the population frequency of these combined 
genetic variations is 2% while nearly half of the Western population is 
overweight/obese. Therefore, we would not consider thromboprophylaxis 
decisions in overweight/obese women such as advice to use non-oral 
contraceptives and the same applies for air travel.  
Strengths of this study include the large patient sample, the detailed 
information about VT risk factors in both patients and controls, and the 
combination with data on prothrombotic genes. A limitation of this study is 
that we did not have full information available for all patients and controls as 
some of them had not reported their BMI (9%) or did not supply DNA 
(19%). Although this may have led to reduced statistical power, it did not 
introduce bias since the frequencies of both factor V Leiden and blood group 
non-O (in patients and controls) were similar to those that have been 
reported previously in unselected populations [19]. Also, the prevalence of 
overweight and obesity in control subjects was similar to that observed in the 
Dutch population (35% overweight and 11% obesity) [20]. Second, height 
and weight were self-reported. As in general persons with underweight tend 
to over report their body weight, while individuals with overweight tend to 
underreport their body weight [21], actual risks will be somewhat higher if 
this phenomenon has occurred.  Third, we analyzed the combination of oral 
contraceptives and hormone replacement therapy, while it would have been 
preferable to analyze these two risk factors separately. Unfortunately, small 
numbers in the control subjects with FV Leiden and/or blood group non-O 
did not enable to look at these two risk factors separately. 
We conclude that individuals with a high BMI, blood group non-O and/or 
factor V Leiden are at high venous thrombosis risk. The high risks of venous 
thrombosis in immobilized individuals with a high BMI, blood group non-O 
and/or factor V Leiden suggests that these individuals are candidates to 
receive (extended) thromboprophylaxis with anticoagulant drugs.    
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Table 2.  Risk of venous thrombosis according to the combinations of BMI tertiles, factor 
















Lowest tertile - O Hormone use 78   (7) 149 (23) Reference 
Median tertile - O Hormone use 50   (4) 83   (13)  1.2  (0.7-1.8) 
Upper tertile - O Hormone use 129 (11) 68   (10) 3.7 (2.4-5.5) 
Lowest tertile - non-O Hormone use 229 (19) 160 (24) 2.7 (1.9-3.8) 
Median tertile - non-O Hormone use 191 (16) 108 (16) 3.3 (2.3-4.8) 
Upper tertile - non-O Hormone use 312 (26) 61   (9) 10.1 (6.8-15.0) 
Lowest tertile + O Hormone use 16   (1.3) 3     (0.5) 10.1 (2.9-35.7) 
Median tertile + O Hormone use 15   (1.2) 7     (1.1) 4.1 (1.6-10.5) 
Upper tertile + O Hormone use 18   (1.5) 5     (0.8) 6.9 (2.5-19.7) 
Lowest tertile + non-O Hormone use 46   (4) 6     (0.9) 14.6 (6.0-35.8) 
Median tertile + non-O Hormone use 47   (4) 3     (0.5) 30.0 (9.1-99.6) 
Upper tertile + non-O Hormone use 78   (7) 7     (1.1) 21.4 (9.4-48.5) 
Lowest tertile - O Travel 22   (3) 134 (17) Reference 
Median tertile - O Travel 31   (5) 119 (15) 1.8 (1.0-3.4) 
Upper tertile - O Travel 73   (11) 116 (15) 4.6 (2.6-8.1) 
Lowest tertile - non-O Travel 97   (14) 138 (18) 4.7 (2.7-7.9) 
Median tertile - non-O Travel 133 (20) 136 (18) 5.9 (3.5-10.0) 
Upper tertile - non-O Travel 197 (29) 125 (16) 11.3 (6.6-19.3) 
Lowest tertile + O Travel 9     (1.3) 4     (0.5) 13.9 (3.9-49.6) 
Median tertile + O Travel 6     (0.9) 11   (1.4) 3.8 (1.2-11.9) 
Upper tertile + O Travel 10   (1.5) 4     (0.5) 18.5 (4.8-71.4) 
Lowest tertile + non-O Travel 22   (3) 9     (1.2) 19.7 (7.4-52.8) 
Median tertile + non-O Travel 33   (5) 13   (1.7) 20.7 (8.5-50.3) 
Upper tertile + non-O Travel 44   (7) 7     (0.9) 44.7 (17.0-117.0) 
Lowest tertile - O Immobile* 98   (8) 54   (17) Reference 
Median tertile - O Immobile 104 (8) 44   (14) 1.2 (0.7-2.0) 
Upper tertile - O Immobile 162 (12) 37   (12) 2.3 (1.4-3.8) 
Lowest tertile - non-O Immobile 172 (13) 51   (16) 1.9 (1.2-3.0) 
Median tertile - non-O Immobile 247 (19) 66   (21) 1.9 (1.2-2.9) 
Upper tertile - non-O Immobile 334 (26) 48   (15) 3.8 (2.4-6.0) 
Lowest tertile + O Immobile 12   (0.9) 2     (0.6) 3.5 (0.-16.1) 
Median tertile + O Immobile 13   (0.9) 1     (0.3) 7.0 (0.9-55.2) 
Upper tertile + O Immobile 21   (1.6) 3     (0.9) 3.6 (1.0-12.6) 
Lowest tertile + non-O Immobile 27   (2) 2     (0.6) 8.6 (1.9-38.1) 
Median tertile + non-O Immobile 47   (4) 2     (0.6) 12.5 (2.9-53.8) 
Upper tertile + non-O Immobile 60   (5) 6     (2) 5.5 (2.2-13.5) 
BMI denotes body mass index (kg/m2); CI 95, 95% confidence interval; OR odds ratio. 
* Defined as bedridden for more than 4 days, surgery, or hospitalization within 3 months prior to 
the index date 
† Odds ratio adjusted for age and sex when appropriate. 
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Table 4.  Risk of venous thrombosis according to the combinations combinations of  















Normal weight - O Hormone use 102 (10) 184 (29) Reference 
Overweight - O Hormone use 76   (7) 75   (12) 1.8 (1.2-2.7) 
Obesity - O Hormone use 76   (7) 31   (5) 4.4 (2.7-7.1) 
Normal weight - non-O Hormone use 313 (31) 209 (33) 2.7 (2.0-3.6) 
Overweight - non-O Hormone use 243 (24) 89   (14) 5.1 (3.6-7.2) 
Obesity - non-O Hormone use 163 (16) 23   (4) 12.6 (7.7-20.8) 
Normal weight + O Hormone use 23   (2) 8     (1) 5.1 (2.2-11.9) 
Overweight + O Hormone use 16   (2) 5     (0.8) 5.7 (2.0-16.1) 
Obesity + O Hormone use 9     (1) 2     (0.3) 7.7 (1.6-36.4) 
Normal weight + non-O Hormone use 75   (7) 7     (1) 19.5 (8.6-43.8) 
Overweight + non-O Hormone use 58   (6) 5     (0.8) 21.0 (8.2-54.0) 
Obesity + non-O Hormone use 37   (4) 4     (0.6) 16.8 (5.8-48.5) 
Normal weight - O Travel 36   (5) 186 (23) Reference 
Overweight - O Travel 61   (9) 139 (17) 2.6 (1.6-4.3) 
Obesity - O Travel 27   (4) 39   (5) 3.6 (1.9-6.8) 
Normal weight - non-O Travel 162 (24) 202 (25) 4.3 (2.8-6.5) 
Overweight - non-O Travel 174 (26)  155 (19) 5.9 (3.9-9.1) 
Obesity - non-O Travel 84   (13) 39   (5) 11.8 (6.9-20.4) 
Normal weight + O Travel 14   (2) 13   (2) 5.6 (2.4-12.9) 
Overweight + O Travel 6     (0.8) 3     (0.4) 13.6 (3.1-60.9) 
Obesity + O Travel 5     (0.7) 3     (0.4) 9.2 (2.0-42.2) 
Normal weight + non-O Travel 35   (5) 14   (2) 16.3 (7.5-35.4) 
Overweight + non-O Travel 43   (6) 12   (1) 21.7 (10.0-47.1) 
Obesity + non-O Travel 21   (3) 3     (0.4) 37.5 (10.5-133) 
Normal weight - O Immobile* 144 (11) 75   (24) Reference 
Overweight - O Immobile 143 (11) 44   (14) 1.6 (1.0-2.5) 
Obesity - O Immobile 69   (5) 14   (4) 2.5 (1.3-4.7) 
Normal weight - non-O Immobile 287 (22) 87   (28) 1.7 (1.2-2.5) 
Overweight - non-O Immobile 312 (24) 51   (16) 3.1 (2.0-4.6) 
Obesity - non-O Immobile 147 (11) 25   (8) 3.0 (1.8-5.0) 
Normal weight + O Immobile 19   (1) 2     (0.6) 5.5 (1.2-24.5) 
Overweight + O Immobile 14   (1) 3     (0.9) 2.0 (0.5-7.3) 
Obesity + O Immobile 13   (1) 1     (0.3) 7.1 (0.9-55.4) 
Normal weight + non-O Immobile 48   (4) 2     (0.6) 14.4 (3.4-61.6) 
Overweight + non-O Immobile 58   (5) 6     (2) 4.9 (2.0-11.9) 
Obesity + non-O Immobile 26   (2) 2     (0.6) 7.2 (1.7-31.2) 
 
BMI denotes body mass index (kg/m2); CI 95, 95% confidence interval; OR odds ratio. 
* Defined as bedridden for more than 4 days, surgery, or hospitalization within 3 months prior to 
the index date 





Chapter	  	  	  5	  
Protein	  S	  levels	  and	  the	  
	  risk	  of	  venous	  thrombosis:	  
	  results	  from	  the	  MEGA	  	  
case-­‐control	  study	  
 
Maria Carolina Pintao 
Daniel D. Ribeiro 
Irene D. Bezemer 
Andrea A. Garcia 
Marieke C.H. de Visser 
Carine J.M. Doggen 
Willem M. Lijfering 
Pieter H. Reitsma 





Protein S levels and the risk of venous thrombosis:  




In thrombophilic families, protein S deficiency is clearly associated with 
venous thrombosis. We aimed to determine whether the same holds true in a 
population-based case-control study (n=5317). Subjects were regarded 
protein S deficient when protein S levels were <2.5th percentile of the 
controls. Free- and total protein S deficiency was not associated with venous 
thrombosis: free protein S <53 U/dL, odds ratio [OR] 0.82 (95%CI, 0.56-
1.21) and total protein S <68 U/dL, OR 0.90 (95%CI, 0.62-1.31). When 
lower cut-off values were applied, it appeared that subjects at risk of venous 
thrombosis could be identified at levels <0.10th percentile of free protein S 
(<33 U/dL, OR 5.4; 95% CI, 0.61-48.8). In contrast, even extremely low 
total protein S levels were not associated with venous thrombosis. PROS1 
was sequenced in 48 subjects with free protein S level <1st percentile (<46 
U/dL), and copy number variations were investigated in 2718 subjects, 
including all subjects with protein S (free or total) <2.5th percentile. 
Mutations in PROS1 were detected in five patients and five controls 
reinforcing the observation that inherited protein S deficiency is rare in the 
general population. Protein S testing and PROS1 testing should not be 




Protein S is a vitamin K-dependent glycoprotein encoded by PROS1 and 
synthesized mainly in hepatocytes and endothelial cells [1]. Protein S 
circulates at a plasma concentration of ~350 nM, of which 40% is free and 
60% is bound to C4b-binding protein [2]. Protein S is a major anticoagulant 
protein that assists in the down-regulation of thrombin formation by 
stimulating the activity of both activated protein C and tissue factor pathway 
inhibitor [3, 4].  
Hereditary protein S deficiency is a haploinsufficiency disorder, associated 
with an increased risk of venous thrombosis [5]. Protein S deficiency is 
associated with decreased activated protein C (APC)-cofactor activity and 
can be classified as type I (decreased levels of both total and free protein S 
antigen), type II (decreased APC-cofactor activity but total and free protein 
S antigen levels within their normal ranges), and type III (decreased levels of 
free protein S antigen levels only) [6]. The genetic basis of protein S 
deficiency is heterogeneous. Currently more than 200 mutations in PROS1 
have been described, the vast majority missense or nonsense mutations [7-9]. 
Sequencing exons and splicing junctions of PROS1 has been successful in 
the identification of a mutation in only around 50% of families with type I or 
mixed type I and type III protein S deficiency [8]. Recently, we and others 
have shown that gross deletions and insertions of PROS1 are present in 
around 30% of the point mutation-negative families with protein S 
deficiency [5, 10, 11].  
Most of the insights regarding the association between protein S deficiency 
and venous thrombosis have been derived from studies of thrombophilic 
families in which there was evidence for inherited protein S deficiency. This 
has led to the notion that the risk of venous thrombosis in protein S deficient 
subjects is five to ten times increased in comparison to non-protein S 
deficient relatives [5, 12-14]. The clinical relevance for the individual patient 
is substantial as subjects with familial protein S deficiency have a first 
venous thrombosis incidence of 0.7% per year [15] and an annual venous 
recurrence risk of 6-10% [14, 16, 17]. It is not clear to what extent the 
conclusions from these family studies can be extrapolated to the general 
population. The co-inheritance of other defects may contribute to or explain 
this effect in families, as was shown for factor V Leiden, and protein C 
deficiency [18, 19]. Evidence obtained from relatively small population-
based studies (maximum number of participants 327) [19] point towards a 
much lower risk of thrombosis associated with protein S deficiency. 
Although some studies reported an up to 2.5 times increased risk, others 
found no increase at all [19-21].   
Due to these uncertainties, we set out to determine in a large population-based 
case-control study whether low levels of free or total protein S were associated 
with an increased risk of venous thrombosis. The molecular basis for protein S 
deficiency was also investigated by analysis of copy number variation of 
PROS1 and resequencing of subjects with the lowest levels of protein S in an 
attempt to support the risk estimates from a genetic viewpoint. 
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The MEGA case-control study has been described in detail previously [22]. 
Consecutive patients aged 18 to 70 years with a first episode of deep venous 
thrombosis or pulmonary embolism between March 1, 1999 and August 31, 
2004 were included, to a total of 4956 patients. Age- and sex-matched 
controls were partners of patients (n=3297) or subjects recruited by random 
digit dialing (RDD) between January 1, 2002 and December 1, 2004 
(n=3000). The participants filled in a questionnaire on potential risk factors 
for venous thrombosis. For logistic reasons, blood sampling was performed 
for participants included up to June 2002. 
 All subjects provided informed consent. The study was approved by the 




Patients in the first half of the study, diagnosed before June 1, 2002 were 
invited, together with their partners as controls, to the anticoagulation clinic 
for a blood sample at least three months after discontinuation of the oral 
anticoagulant therapy. In those patients who continued to take oral 
anticoagulant therapy for more than one year after the event, blood was 
drawn during therapy. Blood was collected into tubes containing trisodium 
citrate 0.106 mol/L as previously described [22]. An additional control group 
was recruited from the population by RDD. DNA was obtained by standard 
methods and was available for 4485 patients and 4889 control subjects.  
Total and free protein S were measured in plasma on a STA-R automated 
coagulation analyzer (Diagnostica Stago, Asnières, France). Total protein S 
was measured by an enzyme-linked immunosorbent assay (ELISA, 
Diagnostica Stago, Asnières, France) and free protein S was measured by an 
immune-turbidimetric method (Diagnostica Stago, Asnières, France), both 




Cut	  off	  points	  
The range from 2.5th-97.5th percentile of both total and free protein S in 
control subjects who did not use vitamin K antagonists at time of blood 
sampling were considered as reference values. We also classified cut off 
points of protein S into different percentiles (i.e. 97.5-75th percentile as 
reference group compared with the 50th-75th percentile, 50th-25th 
percentile, 10th-25th percentile and <10th percentile of the control 
population), to see if this would change our results. Furthermore, a 
sensitivity analysis was performed in which very low protein S levels (i.e. 
less than 0.5th percentile) were compared with the 2.5th-97.5th percentile of 
(free) protein S. We did not include the 97.5-100th percentile in the 
reference population as other studies suggest that high levels protein S may 
be indicative of underlying comorbidity [23]. 
We also constructed cumulative distribution functions to visualize a possible 
difference between free and total protein S levels in patients versus controls. 
For these analyses we excluded patients and controls who used vitamin K 
antagonists at blood draw, were pregnant or used oral contraceptives and 
made a distinction between men, women, and between patients that had 
provoked or unprovoked venous thrombosis. 
 
Genetic	  analysis	  of	  PROS1	  
Copy number variations were analyzed by multiplex ligation-dependent 
probe amplification (MLPA) [24] using the SALSA MLPA KIT P112 
PROS1 (MRC-Holland, Amsterdam, The Netherlands) as previously 
described [11].  
Exons and their flanking regions, and the 5’ and 3’ prime untranslated 
regions were re-sequenced using primers designed to avoid the amplification 
of the highly similar PROSP. After amplification, the PCR product was 
sequenced using an ABI Prism® 3730 DNA Analyzer (Applied Biosystems, 
Carlsbad, California, USA). Primers and PCR conditions are available on 
request. Results were analyzed using vector NTI® software version 10 
(Invitrogen, Paisle, UK).  
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Statistical	  analysis	  	  
With linear regression methods we estimated the effect of vitamin K 
antagonist use, estrogen use, pregnancy and puerperium on protein S levels. 
Based on previously reported aasociations [25], we also estimated the effect 
of obesity on protein S levels. Mean differences were adjusted for age and 
sex, as both age and sex influence protein S levels [26], and for each other in 
a multivariate analysis. Because there is no reason to assume that low levels 
of protein S are more common among partners of patients than in the general 
population, both RDD subjects and partners of patients were considered as 
control subjects and all analyses were unmatched. 
Since protein S levels were collected after venous thrombosis, it is conceivable 
that the event itself influenced protein S levels (‘reverse causation’). To 
analyze the possibility of such a post-hoc phenomenon, we performed a 
sensitivity analysis: scatter diagrams were constructed with regression lines, 
wherein protein S level was plotted against time between venous thrombosis 
and blood sampling (in patients not on vitamin K antagonists). 
Odds ratios with 95% confidence intervals (CIs) were calculated, and were 
adjusted for age and sex by logistic regression methods. Since in the MEGA 
study cases were patients with a first venous thrombosis who were sampled 
from a stable, dynamic population, and since partner controls were matched 
on time to cases and since random controls were selected from the same 
population as the cases, these odds ratios can be interpreted as relative risks 
[27]. Subjects who used vitamin K antagonists at the time of the blood draw 
were excluded when obtaining relative risk estimates. A preplanned 
sensitivity analysis was performed in which we excluded estrogen users and 
pregnant women at the time of the blood draw (as estrogen use and 
pregnancy decrease protein S levels) [28, 29]. To further diminish the 
influence of estrogen related hormones to protein S levels, we restricted an 
analysis to men only. In addition, we assessed the risk of free and total 
protein S deficiency in individuals with a positive family history [30]. 
Stratified analyses were performed in which the common thrombophilias 
(i.e. blood group non-O, factor V Leiden and prothrombin G20210A) were 
compared with normal and low (free) protein S levels. By doing so, one can 
identify possible interaction or confounding of low free and total protein S 
levels to the risk of venous thrombosis by the common thrombophilias. 
All statistical analyses were performed with SPSS for Windows, release 20.0 






Approximately 50% of patients and controls who were included in MEGA 
were tested for free and total protein S levels. No differences in clinical 
characteristics between tested participants and non-tested participants was 
observed, indicating that the tested individuals were representative of the 
whole of MEGA (Table 1). Of note, only 2331 patients were tested on free 
protein S while 2377 patients were tested on total protein S. Of controls, 2872 
were tested on free protein S (n= 1479 partners and n= 1393 RDD controls) 
and 2940 on total protein S (n= 1481 partners and n=1459 controls). That 
some patients or controls were tested on total protein S only and not on free 
protein S was due to technical failures. Both total and free protein S levels 
were as expected reduced in vitamin K antagonist users, in pregnant women, 
and in women using estrogens (Table 2). Protein S levels were higher in 
overweight/ obese control subjects than in those with normal weight.  
 
Risk	  estimates	  
Subjects with low free protein S levels (<2.5th percentile, 53 U/dl) or low total 
protein S levels (<2.5th percentile, < 68 U/dl) were not at increased risk of 
venous thrombosis as compared with subjects with protein S levels in the 2.5th-
97.5th percentile; odds ratio 0.82 (95% CI, 0.56-1.21) and 0.92 (95% CI, 0.63-
1.33), respectively. Acquired conditions such as estrogen use, pregnancy or 
puerperium may transiently decrease protein S levels, which may have 
influenced these findings. We therefore repeated the analysis by excluding all 
women who used estrogens, were pregnant or in puerperium at time of venous 
thrombosis or at time of blood sampling. This adjustment increased the odds 
ratios to 1.51 (95% CI, 0.82-2.78) for subjects with low free protein S levels 
and to 1.34 (95% CI, 0.74-2.44) in subjects with low total protein S levels as 
compared with subjects with protein S levels in the 2.5th-97.5th percentile 
(Table 3). If protein S levels are somehow correlated with lifestyle, patients 
and partners may have been overmatched. To analyze if this occurred, we 
added analyses where patients were only compared with RDD controls. Risk 
estimates for the higher levels of free protein S were somewhat higher than 
when RDD and partner controls were combined. For the lower (free) protein S 
levels, however, risk estimates remained close to 1.0. 
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When we classified subjects into different percentiles (Table 4), again no 
increases in risks for venous thrombosis were observed for lower levels of free 
and total protein S.  
When we restricted the analysis to subjects who did not change hormone use 
status between thrombosis and blood draw, i.e., either consistently used 
hormones at both time points, or did not use hormones at either time point, 
these odds ratios were 1.12 (95% CI, 0.69-1.81), and 0.83 (95% CI, 0.48-
1.44), respectively.  In men, the odds ratio for venous thrombosis in those 
with low free protein S was 2.15 (95% CI, 0.74-6.29). For total protein S 
levels, this odds ratio was 1.57 (95% CI, 0.70-3.49). Interestingly, subjects 
with free protein S levels who were >97.5th percentile appeared to be at 
increased risk of venous thrombosis (odds ratio 1.55; 95% CI, 1.14-2.11), 
which could only partly be attributed to overweight or obesity, as further 
adjustments of overweight or obesity attenuated this odds ratio only 
marginally to 1.48 (95% CI 1.07-2.04) (data not shown).    
To analyze if our results were sensitive to the cut-off level of free or total 
protein S to identify inherited protein S deficiency, we subsequently 
compared decreasing cut-off values of free and total protein S levels, 
respectively, on the risk of venous thrombosis as compared to the reference 
group (subjects with protein S levels that were between the 2.5th-97.5th 
percentile). Although numbers became small, it appeared that a free protein 
S cut off level of < 0.10th (free protein S < 33 U/dL) - 0.20th (free protein S < 
34 U/dL) percentile could identify subjects at high risk of venous thrombosis 
(Figure 1A). Low, or even extremely low (< 0.20th percentile or total protein 
S < 53 U/dL) total protein S levels were not associated with venous 
thrombosis (Figure 1B). Due to small numbers, the latter analysis 
(performed in Figure 1) could not be performed in subjects that were not 
pregnant or were not using hormones.  
As shown in the cumulative distribution functions, patients had as compared 
with controls, slightly higher free protein S levels (mean 100 U/dL in 
patients versus 94 U/dL in controls) and total protein S levels (mean 107 
U/dL in patients versus 105 U/dL in controls) (Figure 2). 
Increased risks for venous thrombosis in protein S deficient subjects are 
mainly reported from thrombophilic family studies. We therefore selected 
patients with a positive family history and repeated the analysis (Table 5). 
Again, no effects were apparent. These null findings could also not be 
explained by confounding of the common thrombophilias or by an 
interaction between the common thrombophilias and low levels of free and 
total protein S (Table 6). 
Because vitamin K antagonist use was self-reported (and therefore we might 
have included subjects with low protein S levels that was due to unreported 
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vitamin K antagonist treatment), we performed an extra sensitivity analysis 
by looking at the distribution of the vitamin K dependent coagulant factors 
(i.e. factors II, VII, IX and X) in cases and control subjects that did not 
report to be on vitamin K antagonist treatment. All factors were normally 
distributed, and there were no apparent outliers in the lower range, 
suggesting that we did not include subjects with low protein S levels that 
was due to vitamin K antagonist treatment. 
 
Genetic	  analysis	  
Copy	  number	  variation	  	  
First, we tested samples from 2270 consecutive MEGA subjects (1395 patients 
and 875 controls). An abnormal MLPA pattern was detected in only one 
individual and the test was repeated confirming the result. This individual was 
a female patient of 66 years old who was not using estrogens or vitamin K 
antagonists at the moment of thrombosis or sample collection. She had an 
unprovoked first venous thrombosis and her family history was not available. 
The patient was heterozygous for a complete deletion of PROS1. Her total 
protein S was 64 U/dL (< 2.5th percentile of the control group), and her free 
protein S was 22 U/dL (< 2.5th percentile of the control group).  
The presence of only one copy number variation in 2270 samples shows that 
copy number variation of PROS1 is at most a rare cause of venous 
thrombosis, and a rare finding in a normal population. To verify this, we 
zoomed in on potentially protein S deficient subjects by selecting DNA from 
all subjects with low (i.e. lower than the 2.5th percentile of the control group) 
total or low free protein S. Patients who used vitamin K-antagonists at the 
time of the blood draw were also included to guarantee that protein S 
deficient subjects were not missed. In total, 191 new samples were selected 
(84 patients and 107 controls), in which no new copy number variation of 
PROS1 was identified.  
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Sequencing	  of	  PROS1	  	  
To further investigate the molecular basis of protein S deficiency, we 
selected the first 48 subjects with the lowest levels of free protein S. All 
these subjects were below the 1st percentile from the controls (cutoff < 46 
U/dL); of the 48 selected subjects 24 were patients and 24 were controls. For 
this analysis, patients using vitamin K antagonists were excluded. 
Eleven non-synonymous variations were identified in ten subjects (5 patients 
and 5 controls); one of these subjects (subject 25) is carrier of two different 
variations. The variations identified included: 1 complete deletion, 1 indel, 7 
missense and 1 nucleotide substitution in the regulatory 3’-untranslated 
region. Table 7 summarizes the results and gives references for variations 
previously described. Subjects are numbered according to increasing levels 
of free protein S. PROS1 coding DNA reference sequence is NM_000313.3 
and protein reference sequence is NP_000304.2. 
Four variations were novel; subject 2 (patient) carried an indel mutation 
(Phe323fs) in the SHBG-like domain that is predicted to result in a truncated 
protein; subject 17 (patient) carried a 684C>G (Cys228Trp) substitution in 
the EGF-domain 3; subject 12 (control) carried a nucleotide substitution in 
the 3’UTR; and subject 45 (control) carried a 1095T>G (Asn365Lys) 
substitution in the SHBG-like domain. 
A complete deletion of PROS1 was detected in subject 4 (patient). Subject 6 is 
a patient who carried a 431C>A (Thr144Asn) substitution in the EFG-domain 
1.  Protein S Heerlen (Ser501Ala) was detected in two control subjects 
(subjects 25 and 32), and one carrier of protein S Heerlen (subject 25) carried 
also a second variation in the SHBG-like domain (13012T>C; Val434Ala). 
This variation is known as dbSNP (rs6803112) with a reported minor allele 
frequency (MAF) of 0.097. Subject 43 (control) carried a 698G>A 
(Arg233Lys) substitution, which is also listed in dbSNP (rs41267007, MAF 
0.002). Finally, control subject 44 carried an 814G>A (Gly272Arg) variation 
in the EGF-domain 4. This variation is listed in dbSNP (rs41267005, MAF 




Conflicting data have been reported regarding venous thrombotic risk in 
subjects with protein S deficiency within the community [2]. In the present 
study, subjects with low levels of free protein S had an increased risk of 
unprovoked venous thrombosis (odds ratio 2.31; 95% CI, 1.06-5.05). 
However, the prevalence of patients with such levels was low (n=8, or 0.4% 
of the total patient population), making it unpractical to use free protein S 
levels to help identify patients at risk in a clinical setting. The present study, 
confirms the results of a previous population based case-control study 
(Leiden Thrombophilia Study) [20], where only very low levels of free 
protein S (i.e. < 0.10th percentile or < 33 U/dL), but not of total protein S, 
were associated with an increased risk for venous thrombosis (odds ratio 
5.44; 95% CI, 0.61-48.78). This increased risk at very low free protein S 
levels corresponds to some extent with findings from family studies of 
protein S deficiency on venous thrombosis risk (although relative risk 
estimates in family studies for first venous thrombosis in subjects with very 
low free protein S levels are even higher than 5) [12, 31], as well as the 
finding from family studies that showed that the cut off level of free protein 
S to identify true inherited protein S deficiency lies far below the commonly 
used normal range [12, 14]. Total protein S levels were not able to identify 
subjects at risk of venous thrombosis even when these levels were very low. 
This is in agreement with studies where free protein S was a better indicator 
of venous thrombosis risk than total protein S [32]. Nevertheless, as shown 
by its broad confidence interval, this analysis suffers from small sample size 
(n=7 of the patient population), indicating that even if very low free protein 
S levels are associated with venous thrombosis, large numbers of patients 
with venous thrombosis will need to be tested to identify only a few with a 
true free protein S deficiency. Such a strategy is unlikely to become 
clinically useful.  
Many patients with venous thrombosis who are on anticoagulant treatment at 
the time of the blood sampling are identified with a protein S deficiency, 
which is thought to have clinical consequences [17, 33]. However, both our 
study and previous studies show reduced protein S levels in vitamin K 
antagonist and oral contraceptive users in the absence of a known true 
(genetic) deficiency [34, 35]. This reinforces the importance of avoiding the 
collection of blood for protein S measurement at moments when acquired 
deficiency can be present.  
Molecular analysis of PROS1 in 48 subjects with very low levels of protein 
S (below the 1st percentile) identified mutations in only ten subjects. This 
finding suggests that inherited protein S deficiency is rare in the general 
population and in patients with thrombosis. It is important to note, however, 
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that our analysis was limited to copy number variations, exons and their 
flanking regions, and the 5’- and 3’-UT regions. We cannot exclude that 
genetic variations, for example in introns or in promoter regions not covered 
in the present experiments, could play a role in protein S deficiency. 
Mutations were equally distributed among patients and controls. However, 
three out of six patients with protein S levels below percentile 0.2 carried 
mutations that are likely to be detrimental (complete deletion of PROS1, 
967delTinsGG and Thr144Asn). In contrast, mutations in controls were 
likely not to be detrimental. Protein S Heerlen (known to be associated with 
type III protein S deficiency) was detected in two controls. Another control 
carried a variation previously described as a neutral polymorphism 
(Arg233Lys) and a final control carried a variation in the 3’- UT region.  
PROS1 deletion was present in only one patient, showing that gross copy 
number variation of PROS1 is rare in the general population.  
Some aspects of our study need additional comment. First, we have noted 
that high levels of free protein S were associated with an increased risk of 
venous thrombosis in our study. Interestingly, high levels of free protein S 
have been associated with an increased risk of coronary heart disease in 
another study [36]. Free protein S has been described as a semi-delayed 
acute phase reactant [19, 37] and protein S levels have been described to be 
higher, on average, in overweight/obese control subjects than in controls 
subjects with normal weight [25]. Obesity is associated with a chronic 
inflammatory status and with increased risk for venous thrombosis [38]. It is 
possible that high levels of free protein S are a consequence of the former. 
However, adjustment for overweight and obesity only attenuated the risk of 
venous thrombosis associated with high levels of free protein S, suggesting 
that other mechanisms could play a role.  
Second, our study is a case-control study in which the blood sample was 
collected after the thrombotic event. Therefore, we cannot exclude the 
possibility that differences in plasma levels of protein S in patients and 
control subjects were the result of the thrombotic event itself. However, the 
blood draw was performed at least 3 months after the thrombotic event, and 
it is unlikely that the thrombotic event itself caused persistent abnormalities 
in protein S levels. Furthermore, no differences in protein S levels were 
observed between patients in whom blood was drawn 3-6 months after their 
thrombotic event compared with those in whom the blood draw took place 
later (e.g. more than 6-9, 9-12 or >12 months).  
Third, we only had one measurement of free and total protein S. This may 
have led to misclassification of protein S deficiency when protein S levels 
fluctuate due to transient acquired conditions. However, only use of female 
hormones and vitamin K antagonists are known determinants of protein S 
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levels. Sensitivity analyses in which oral contraceptives, and pregnant or 
puerperic women were excluded did not materially affect our risk estimates 
for total protein S, but did slightly for free protein S. Moreover subjects who 
were still on vitamin K antagonists at time of blood draw were excluded 
from analyses where relative risk estimates where determined. Finally, 
qualitative analysis of protein S was not performed, as the laboratory 
analysis of protein S activity levels is known to produce spurious false low 
levels. Therefore, we may have missed individuals with type II protein S 
deficiency [39].  
In summary, low free protein S and low total protein S levels could at best 
rarely identify subjects at risk for venous thrombosis in a population based 
study. Only when cut off levels for free protein S were far below the normal 
range or when unprovoked venous thrombosis was considered as outcome 
event, we found a 2- to 5-fold increased risk of venous thrombosis, which is 
far below the relative risk estimates that are obtained for free protein S in 
family based studies. Protein S testing and subsequent testing on PROS1 
mutations should therefore not be considered in unselected patients with 
venous thrombosis.  
  
Protein S levels and the risk of venous thrombosis:  




1. Fair DS, Marlar RA. Biosynthesis and secretion of factor VII, protein C, 
protein S, and the Protein C inhibitor from a human hepatoma cell line. 
Blood. 1986;67(1):64-70. 
2. Dahlbäck B. The tale of protein S and C4b-binding protein, a story of 
affection. Thromb Haemost. 2007;98(1):90-96. 
3. Walker FJ. Protein S and the regulation of activated protein C. Seminars 
in thrombosis and hemostasis. 1984;10(2):131-138. 
4. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates 
inhibition of the tissue factor pathway by tissue factor pathway inhibitor. 
Proceedings of the National Academy of Sciences of the United States of 
America. 2006;103(9):3106-3111. 
5. Castoldi E, Maurissen LF, Tormene D, et al. Similar hypercoagulable 
state and thrombosis risk in type I and type III protein S-deficient 
individuals from families with mixed type I/III protein S deficiency. 
Haematologica. 2010;95(9):1563-1571. 
6. Boyer-Neumann C, Bertina RM, Tripodi A, et al. Comparasion of 
funcional assays for protein S: European collaborative study of patients 
with congenital and acquired deficiency. Thrombosis and haemostasis. 
1993;70(6):946-950. 
7. Gandrille S, Borgel D, Sala N, et al. Protein S deficiency: a database of 
mutations--summary of the first update. Thrombosis and haemostasis. 
2000;84(5):918. 
8. García de Frutos P, Fuentes-Prior P, Hurtado B, Sala N. Molecular basis 
of protein S deficiency. Thromb Haemost. 2007;98(3):543-556. 
9. Stenson PD, Mort M, Ball EV, et al. The Human Gene Mutation 
Database: 2008 update. Genome medicine. 2009;1(1):13. 
10. Johansson AM, Hillarp A, Säll T, Zöller B, Dahlbäck B, Halldén C. 
Large deletions of the PROS1 gene in a large fraction of mutation-
negative patients with protein S deficiency. Thromb Haemost. 
2005;94(5):951-957. 
11. Pintao MC, Garcia AA, Borgel D, et al. Gross deletions/duplications in 
PROS1 are relatively common in point mutation-negative hereditary 
protein S deficiency. Hum Genet. 2009;126(3):449-456. 
12. Makris M, Leach M, Beauchamp NJ, et al. Genetic analysis, phenotypic 
diagnosis, and risk of venous thrombosis in families with inherited 
deficiencies of protein S. Blood. 2000;95(6):1935-1941. 
Chapter 5 
 74 
13. Ten Kate MK, Platteel M, Mulder R, et al. PROS1 analysis in 87 
pedigrees with hereditary protein S deficiency demonstrates striking 
genotype-phenotype associations. Hum Mutat. 2008;29(7):939-947. 
14. Lijfering WM, Mulder R, ten Kate MK, Veeger NJ, Mulder AB, van der 
Meer J. Clinical relevance of decreased free protein S levels: results 
from a retrospective family cohort study involving 1143 relatives. Blood. 
2009;113(6):1225-1230. 
15. Vossen CY, Conard J, Fontcuberta J, et al. Risk of a first venous 
thrombotic event in carriers of a familial thrombophilic defect. The 
European Prospective Cohort on Thrombophilia (EPCOT). Journal of 
thrombosis and haemostasis. 2005;3(3):459-464. 
16. Vossen CY, Walker ID, Svensson P, et al. Recurrence rate after a first 
venous thrombosis in patients with familial thrombophilia. Arteriosclerosis, 
thrombosis, and vascular biology. 2005;25(9):1992-1997. 
17. Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for 
thrombophilia in patients with first venous thrombosis: results from a 
retrospective family cohort study on absolute thrombotic risk for 
currently known thrombophilic defects in 2479 relatives. Blood. 
2009;113(21):5314-5322. 
18. Zöller B, Berntsdotter A, García de Frutos P, Dahlbäck B. Resistance to 
activated protein C as an additional genetic risk factor in hereditary 
deficiency of protein S. Blood. 1995;85(12):3518-3523. 
19. Faioni EM, Valsecchi C, Palla A, Taioli E, Razzari C, Mannucci PM. 
Free protein S deficiency is a risk factor for venous thrombosis. Thromb 
Haemost. 1997;78(5):1343-1346. 
20. Koster T, Rosendaal FR, Briët E, et al. Protein C deficiency in a 
controlled series of unselected outpatients: an infrequent but clear risk 
factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 
1995;85(10):2756-2761. 
21. Liberti G, Bertina RM, Rosendaal FR. Hormonal state rather than age 
influences cut-off values of protein S: reevaluation of the thrombotic risk 
associated with protein S deficiency. Thromb Haemost. 
1999;82(3):1093-1096. 
22. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, 
prothrombotic mutations, and the risk of venous thrombosis. JAMA : the 
journal of the American Medical Association. 2005;293(6):715-722. 
23. Borgel D, Duchemin J, Alhenc-Gelas M, Matheron C, Aiach M, Gandrille 
S. Molecular basis for protein S hereditary deficiency: genetic defects 
Protein S levels and the risk of venous thrombosis:  
results from the MEGA case-control study 
 
 75 
observed in 118 patients with type I and type IIa deficiencies. The French 
Network on Molecular Abnormalities Responsible for Protein C and 
Protein S Deficiencies. J Lab Clin Med. 1996;128(2):218-227. 
24. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, 
Pals G. Relative quantification of 40 nucleic acid sequences by multiplex 
ligation-dependent probe amplification. Nucleic Acids Res. 
2002;30(12):e57. 
25. Mulder R, van Schouwenburg IM, Mahmoodi BK, et al. Associations 
between high factor VIII and low free protein S levels with traditional 
arterial thrombotic risk factors and their risk on arterial thrombosis: 
results from a retrospective family cohort study. Thrombosis research. 
2010;126(4):e249-254. 
26. Henkens CM, Bom VJ, Van der Schaaf W, et al. Plasma levels of protein 
S, protein C, and factor X: effects of sex, hormonal state and age. 
Thrombosis and haemostasis. 1995;74(5):1271-1275. 
27. Knol MJ, Vandenbroucke JP, Scott P, Egger M. What do case-control 
studies estimate? Survey of methods and assumptions in published case-
control research. Am J Epidemiol. 2008;168(9):1073-81. 
28. Middeldorp S, Meijers JC, van den Ende AE, et al. Effects on 
coagulation of levonorgestrel- and desogestrel-containing low dose oral 
contraceptives: a cross-over study. Thrombosis and haemostasis. 
2000;84(1):4-8. 
29. Said JM, Ignjatovic V, Monagle PT, Walker SP, Higgins JR, Brennecke 
SP. Altered reference ranges for protein C and protein S during early 
pregnancy: Implications for the diagnosis of protein C and protein S 
deficiency during pregnancy. Thrombosis and haemostasis. 
2010;103(5):984-988. 
30. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen 
CJ. The value of family   history as a risk indicator for venous 
thrombosis. Arch Intern Med. 2009.23;169(6):610-5. 
31. Mulder R, Ten Kate MK, Kluin-Nelemans HC, Mulder AB. Low cut-off 
values increase diagnostic performance of protein S assays. Thrombosis 
and haemostasis. 2010;104(3):618-625. 
32. ten Kate MK, van der Meer J. Protein S deficiency: a clinical 
perspective. Haemophilia : the official journal of the World Federation 
of Hemophilia. 2008;14(6):1222-1228. 
33. Brouwer JL, Lijfering WM, Ten Kate MK, Kluin-Nelemans HC, Veeger 
NJ, van der Meer J. High long-term absolute risk of recurrent venous 
Chapter 5 
 76 
thromboembolism in patients with hereditary deficiencies of protein S, 
protein C or antithrombin. Thrombosis and haemostasis. 
2009;101(1):93-99. 
34. Tans G, Curvers J, Middeldorp S, et al. A randomized cross-over study 
on the effects of levonorgestrel- and desogestrel-containing oral 
contraceptives on the anticoagulant pathways. Thrombosis and 
haemostasis. 2000;84(1):15-21. 
35. Hansen AT, Andreasen BH, Salvig JD, Hvas AM. Changes in fibrin D-
dimer, fibrinogen, and protein S during pregnancy. Scandinavian journal 
of clinical and laboratory investigation. 2011;71(2):173-176. 
36. Ken-Dror G, Cooper JA, Humphries SE, Drenos F, Ireland HA. Free 
protein S level as a risk factor for coronary heart disease and stroke in a 
prospective cohort study of healthy United Kingdom men. American 
journal of epidemiology. 2011;174(8):958-968. 
37. Toulon P, Gandrille S, Vitoux JF, Fiessinger JN, Sultan Y, Aiach M. 
High total and free protein S in patients with acute deep vein thrombosis. 
Thrombosis research. 1990;59(1):213-217. 
38. Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity 
and thrombosis. European journal of vascular and endovascular 
surgery: the official journal of the European Society for Vascular 
Surgery. 2007;33(2):223-233. 
39. Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review 
of the technical, diagnostic, and epidemiologic considerations for protein 
S assays. Arch Pathol Lab Med. 2002;126(11):1349-1366. 
40. Gandrille S, Borgel D, Eschwege-Gufflet V, et al. Identification of 15 
different candidate causal point mutations and three polymorphisms in 
19 patients with protein S deficiency using a scanning method for the 
analysis of the protein S active gene. Blood. 1995;85(1):130-138. 
41. Espinosa-Parrilla Y, Yamazaki T, Sala N, Dahlback B, de Frutos PG. 
Protein S secretion differences of missense mutants account for 
phenotypic heterogeneity. Blood. 2000;95(1):173-179. 
42. Rezende SM, Lane DA, Zoller B, et al. Genetic and phenotypic 
variability between families with hereditary protein S deficiency. 
Thromb Haemost. 2002;87(2):258-265. 
43. den Dunnen JT, Antonarakis SE. Mutation nomenclature extensions and 
suggestions to describe complex mutations: a discussion. Human 
mutation. 2000;15(1):7-12. 
Protein S levels and the risk of venous thrombosis:  






Protein S levels and the risk of venous thrombosis:  





Protein S levels and the risk of venous thrombosis:  








Protein S levels and the risk of venous thrombosis:  








Protein S levels and the risk of venous thrombosis:  







Figure 2. Cumulative distribution functions of free and total protein S 
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ABSTRACT	  
Venous thrombosis, including deep vein thrombosis and pulmonary 
embolism, is a common disease that frequently recurs. Recurrence can be 
prevented by anticoagulants, but this comes at the risk of bleeding. 
Therefore, assessment of the risk of recurrence is important to balance the 
risks and benefits of anticoagulant treatment. This review briefly outlines 
what is currently known about the epidemiology of recurrent venous 
thrombosis, and focuses in more detail on potential new risk factors for 
venous recurrence. The general implications of these findings in patient 




Pulmonary embolism and deep vein thrombosis are part of the spectrum of a 
single disease defined as venous thrombosis, which occurs in approximately 
1-2 per 1000 persons per year [1]. Approximately 30% of the apparently 
isolated episodes of pulmonary embolism are associated with silent deep 
vein thrombosis [2]. In patients presenting symptoms of deep vein 
thrombosis, the frequency of silent pulmonary embolism ranges between 40 
and 50% [3]. The short-term death rate due to pulmonary embolism is 3-6% 
[1,4]. A common complication of deep vein thrombosis is the post-
thrombotic syndrome, which occurs in up to 50% of patients [5].  
Venous thrombosis can recur and its recurrence rate (after stopping 
anticoagulant treatment) is 25% within 5 years [6,7]. Although many clinical 
and laboratory risk factors for first venous thrombosis have been established 
[8], only a few of these risk factors are known to play a role in the prediction 
of a recurrent event (Table 1) [9,10]. Recurrent venous thrombosis usually 
leads to a decision for life-long anticoagulant treatment, which substantially 
increases long-term health care costs. Furthermore, anticoagulation is 
associated with serious potential side effects such as major bleeding. 
Therefore, efforts are required to reduce the risk of recurrent venous 
thrombosis while minimizing the use of anticoagulant treatment. This 
requires the identification of factors associated with recurrence.  
This review briefly outlines what is currently known about the epidemiology 
of recurrent venous thrombosis, and also focuses in more detail on potential 
new risk factors for venous recurrence. The general implications of these 
findings in patient management are discussed. 
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CURRENTLY	  KNOWN	  RISK	  FACTORS	  FOR	  
THE	  RECURRENCE	  OF	  VENOUS	  
THROMBOSIS	  
The risk of thrombosis recurrence is especially high in patients in whom the 
initial venous thrombosis was unprovoked (i.e., the event occurred in the 
absence of transitory risk factors including surgery, hospitalization, 
immobilization, and oral contraceptive use or pregnancy/puerperium) [11-
13]. It is important to keep in mind that, as long as the risk factor that caused 
the thrombosis is present the increased risk remains. This is especially 
important in patients with active cancer, who have a high risk of recurrence 
even during vitamin K antagonist treatment [14,15]. Women who had a first 
venous thrombotic event that was associated with concurrent oral 
contraceptive use are at high risk for recurrence when they do not refrain 
from oral contraceptives after the event occurred. This is illustrated by the 
LETS-follow-up study where 40% of women continued, started or restarted 
oral contraceptive use during follow-up. These women had a 4.6-fold 
(95%CI = 1.9-11.5) higher recurrence rate than women in the same age 
group (16-48 years) who stopped using oral contraceptives after their first 
event, and who were not pregnant during follow-up [recurrence rate of 
48.8/1000 person/years (95%CI = 24.3-87.2) for oral contraceptive use 
versus 10.5/1000 person/years (95%CI = 4.5-20.7) in no hormonal 
contraception or pregnancy] [16].  
After discontinuation of anticoagulant therapy the annual risk of recurrence 
among patients with antiphospholipid syndrome may be as high as 50 to 67%, 
especially during the first few months [17]. Most clinicians therefore opt to treat 
venous thrombosis patients with strict diagnostic criteria for antiphospholipid 
syndrome, [18] with long-term anticoagulant treatment [11,19].  
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Recent studies have shown that men have a 2-4-fold higher risk of recurrent 
venous thrombosis than women [16,20,21]. The reason why men would be at 
higher risk of recurrent venous thrombosis than women is unknown. It could 
be explained by an imbalance of environmental risk factors for venous 
thrombosis in men compared to women, for example, due to hormonal risk 
factors to which only women are exposed. As oral contraceptives are 
discouraged after first venous thrombosis and thromboprophylaxis is often 
recommended in women during pregnancy or puerperium after a first event 
[22,23], women may have a lower thrombosis potential level for recurrence 
than men in whom environmental risk factors are less often associated with 
risk for a first venous thrombosis [24]. Some studies indeed suggested that 
the lower risk of recurrent venous thrombosis in women could be explained 
by a reduced rate of recurrence after venous thrombosis associated with oral 
contraceptive use or pregnancy [24-26]. However, a recent meta-analysis 
concluded that the lower risk of recurrent venous thrombosis in women 
could not to be fully accounted for by a reduced rate of recurrence after 
venous thrombosis associated with oral contraceptive use or pregnancy [27]. 
Whether or not male sex in itself is a potential factor in the development for 
recurrent venous thrombosis is still unclarified; nevertheless, it is a clear 
predictor of an increased recurrence risk. 
 
Age	  	  
Although age is a strong risk factor for first venous thrombosis, it seems to 
have no effect on the risk of recurrence. Some authors have reported a 
slightly increased risk (hazard ratio 1.36 per increase in each decade of age) 
[28,29], and others found no relationship [6,30,31], or even a decreased risk 
with ageing [32]. In routine clinical practice, age at first venous thrombosis 
is usually taken into consideration when a patient is counseled regarding 
duration of anticoagulant treatment. Some clinicians are reluctant to treat 
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elderly patients with anticoagulants for a long period of time because they 
consider risk of bleeding rather than risk of venous recurrence as the 
determinant for duration of anticoagulation. Others, in contrast, are hesitant 
to recommend extended anticoagulation to younger patients because they 
assume that these patients may have a low recurrence risk. Many younger 
individuals dislike long-term anticoagulation simply because of the prospect 
of a long-time medical treatment. According to previous findings, the risk of 
recurrence is similar for younger and older patients. Therefore, age at first 
venous thrombosis should not matter when determining how long patients 
with thrombosis should receive anticoagulation, provided their risk of 
bleeding is low [30]. 
 
Overweight/obesity	  	  
Obesity is a risk factor for first and recurrent venous thrombosis [33,34]. It is 
not completely understood why obesity predisposes to venous thrombosis. 
People with overweight or obesity tend to be more immobile, which may lead 
to clot formation through stasis. It is also possible that these individuals 
acquire a prothrombotic state. Indeed, studies have shown an association 
between increase in body mass index (BMI) and factor VIII levels [35], which 
is a risk factor for venous thrombosis [36]. Adipose tissue may contribute to 
enhanced coagulation by direct tissue factor production, but 
hypercoagulability could also be due to direct effects of adipose tissue on the 
hepatic synthesis of coagulation factors [37,38]. Another explanation is that 
estrogen levels are higher in obese men and women due to an increased 
conversion from androgen to estrogen in adipose tissue [39]. As estrogens and 
progestagens are prothrombotic [40], this may also be a possible pathway. A 
third explanation may be that obesity is considered to be a chronic low-grade 
inflammatory state, which may result in increases of clotting factors leading to 
venous thrombosis [38]. It seems plausible that weight loss can reduce the risk 
of recurrent venous thrombosis [30], although prospective follow-up studies 
on this issue have not been performed. 
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SPECIFIC	  ASPECTS	  RELATED	  TO	  
THROMBOSIS	  	  
	  
Risk	  situations	  for	  venous	  thrombosis	  that	  
happened	  in	  the	  past	  but	  not	  related	  with	  a	  
thrombotic	  event	  
Some patients with first venous thrombosis may have experienced many risk 
situations for thrombosis during their life time without actually developing 
it, while others may have experienced few of such risk situations and then 
developed venous thrombosis idiopathically or after a single provoked risk 
factor. In a previous study we hypothesized that those who had 'survived' 
many risk situations without developing venous thrombosis would, have a 
lower recurrence risk after a first event [41]. In this Brazilian cohort, risk 
situations for venous thrombosis that occurred in the past but did not result 
in venous thrombosis at that time were noted in 66% of patients. Although 
the high rate of positive responders to this question provided a large group to 
evaluate our hypothesis, the risk of patients with unprovoked venous 
thrombosis with or without past risk situations was still 3-fold higher than 
the risk of those who had a provoked risk factor present at time of first 
venous thrombosis. Hence, asking patients with venous thrombosis about 
risk situations for venous thrombosis that took place long before their first 
thrombotic event seems to be of little value for predicting if an individual 
patient has a low risk for thrombosis recurrence. 
 
Infections	  
A recent prospective population-based cohort study showed that elevated C-
reactive protein (CRP) levels were associated with an increased risk of 
venous thrombosis [42]. Interestingly, it was shown that this risk was highest 
when CRP levels were elevated during the period just before the onset of 
venous thrombosis. This latter finding supports the hypothesis that the 
coagulation system can be stimulated by transient infection [43], which has 
also been suggested by experimental studies [44]. Two retrospective cohort 
studies showed that patients with a transient infection such as urinary tract 
infection or pneumonia had a 2- to 3-fold increased risk of acute venous 
thrombosis [45,46]. Thus, in the presence of a transient infection, a clinician 
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could decide to withhold anticoagulant treatment after 3-6 months in a 
person with a first venous thrombosis at the time of such an episode of 
infection or inflammation. This approach is supported by the study by Baglin 
et al. [47] and is recommended by the ACCP Guidelines, based on a low risk 
of thrombotic recurrence when the provoking risk factor is known and 
transient [11]. However, because infections may also lead to transient 
periods of immobilization or hospitalization, this increased risk could also be 
explained by a concurrent period of immobilization leading to venous stasis 
that ultimately leads to thrombosis. Whether common transient or 
inflammatory diseases should therefore be considered as provoking risk 
factors for venous thrombosis is uncertain.  
 
Thrombophilia	  	  
Thrombophilia can be identified in about half of all patients presenting 
venous thrombosis, and appears to provide at least a partial explanation for a 
previously poorly explained disease. Over the past decades, testing has 
increased tremendously for various indications, but whether the results of 
such tests aid the clinical management of patients has not been settled [48]. 
There is weak evidence that testing for thrombophilia could improve the risk 
prediction for venous thrombosis recurrence.  Those with positive tests have 
at most a small increase in the risk of recurrence [7,9,49]. The association 
between natural anticoagulant deficiencies (protein C, protein S, 
antithrombin) and an increased risk of venous recurrence has been 
established [50,51], but the clinical relevance of this association is unknown. 
There is no proof that screening for thrombophilia helps patients with regard 
to treatment of the acute event or for prevention of recurrence [7,47,52].  
 
Mode	  of	  first	  event	  presentation	  	  
The mode of presentation of venous thrombosis, as deep vein thrombosis or 
pulmonary embolism, could predict the likelihood and type of recurrence. In 
a recent meta-analysis on this issue, the risk for recurrence as pulmonary 
embolism was 3.1-fold greater in patients presenting with previous 
symptomatic pulmonary embolism than in patients with previous proximal 
deep vein thrombosis. Patients with proximal deep vein thrombosis had a 
4.8-fold higher cumulative recurrence rate than those with distal deep vein 
thrombosis [53]. High risk of pulmonary embolism at recurrence in patients 
with an initial pulmonary embolism has been shown repeatedly [54-56]. It is 
not clear why patients with pulmonary embolism have a higher chance of 
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recurrence than patients with deep vein thrombosis [55-58]. However, given 
that the risk of fatal pulmonary embolism is two to four times higher in 
patients with symptomatic pulmonary embolism and the risk of chronic 
pulmonary embolism and pulmonary hypertension is 15 to 20 times more 
likely when the pulmonary embolism is recurrent [57,59,60], the mode of 
initial presentation appears to be an important factor in determining the 
duration of anticoagulant therapy in individual patients after a first episode 
of venous thrombosis. The current recommendation for anticoagulation 
duration is already shorter for patients with distal venous thrombosis [11]. 
However, more studies are needed in order to support different 
recommendations for the management of pulmonary embolism and proximal 
deep vein thrombosis. 
 
Residual	  vein	  thrombosis	  	  
The presence of sequelae in the area affected by venous thrombosis is a possible 
risk factor for recurrence [61]. Two interventional studies used residual vein 
thrombosis to guide the duration of anticoagulation treatment after unprovoked 
proximal deep vein thrombosis [62,63]. Tailoring the duration of oral 
anticoagulant therapy on the basis of findings of repeated leg vein 
ultrasonography reduced the risk for recurrent venous thrombosis by 35% 
compared to the administration of conventional, fixed time treatment without an 
appreciable increase in hemorrhagic risk [62]. However, many patients without 
sequelae relapsed; therefore this assessment reduces, but does not exclude the 
possibility to misclassify patients as a being at low risk for recurrence [62]. 
Because there are currently no uniformly acknowledged criteria for the 
definition of vein decimalization, any clinical decision made on the basis of 
residual vein thrombosis assessment can only be premature [9,12,64].  
	  
D-­‐dimer	  testing	  	  
D-dimer levels have been used as a predictive test for recurrence of venous 
thrombosis when remaining high after 30 days of discontinuation of oral 
anticoagulation [65]. An Italian multicenter interventional trial (PROLONG) 
evaluated adult patients after a first event of unprovoked venous thrombosis 
who were treated for at least three months with oral anticoagulants. The 
relative risk of events (recurrence or bleeding) was four-times higher in 
patients with abnormal D-dimer levels who had not resumed anticoagulation 
compared to those who restarted the anticoagulation [65]. The risk of 
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recurrence in patients with unprovoked venous thrombosis and normal D-
dimer levels was similar to that of patients with a first provoked episode of 
venous thrombosis [66]. In the PROLONG II study, published in 2010, the 
Italian investigators reported that repeated testing of D-dimer concentrations 
after withdrawal of anticoagulation treatment following a first episode of 
unprovoked venous thrombosis could help establish the optimum duration of 
treatment [67]. Although these results are encouraging, it should be 
remembered that the positive predictive value of a high D-dimer 
concentration regarding recurrent venous thrombosis is low and therefore not 
very helpful for clinical decision making [68]. The measurement of D-dimer 
might be more useful in identifying patients at low risk of recurrence in 
whom the risk of bleeding during long-term anticoagulation might be higher 
than the risk of recurrence after stopping treatment. 
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RISK	  ASSESSMENT	  IN	  PATIENTS	  WITH	  
UNPROVOKED	  FIRST	  VENOUS	  
THROMBOSIS	  
A recently introduced approach for the assessment of risk for recurrent 
venous thrombosis is the combination of clinical characteristics of the 
patients (i.e., location of the thrombus, sex, or age) with laboratory or 
imaging tests. Rodger et al. [32] identified that a combination of 2 or more 
of the following risk factors in women: absence of symptoms suggestive of 
post-thrombotic syndrome, D-dimer concentration during anticoagulation 
treatment <250 ng/mL, body-mass index <30 kg/m2, and age <65 years, 
could be predictive of a low recurrence risk. No combination of predictors 
identified a low-risk group of men. Following the same principles as those of 
the study by Rodger et al., Eichinger et al. [69] developed a nomogram that 
can be used to calculate risk scores and expected cumulative recurrence 
rates. The variables used were: sex, location of initial venous thrombosis and 
D-dimer levels in individual patients. Both prediction models need to be 
validated before they can be used in clinical care. 
In summary, prevention of recurrent venous thrombosis will be more 
profitable if it becomes possible both to identify more precisely those 
persons who are at risk of recurrent venous thrombosis and to quantify the 
risk to which they are exposed. Consideration of the discussed new risk 
factors for recurrence may allow us a more optimal use of prophylactic 
strategies against recurrent venous thrombosis. More research on this topic is 
needed before conclusions can be drawn. 
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Table 1. Risk factors for recurrent venous thrombosis. 
Genetic Acquired Environmental Mixed or not well established 
Antithrombin 
deficiency Malignancy Surgery and major trauma High factor VIII 
Protein C deficiency Antiphospholipid antibodies Pregnancy and puerperium High D-dimer 
Protein S deficiency  Oral contraceptives Factor V Leiden 
  Hormone replacement therapy Prothrombin G20210A 
  Prolonged immobilization Infection 
   Sex 
   Obesity 
   Past risk situations 
   Residual vein thrombosis 
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ABSTRACT	  
Objective: Strategies that can classify the risk for recurrent venous 
thrombosis are needed. Some patients may have experienced many risk 
situations during their life time without developing venous thrombosis (VT), 
while others may have experienced few of such risk factors and then develop 
VT idiopathically or after a single provoked risk factor. We hypothesized 
that those who had 'survived' many risk situations without developing VT 
would, after a first VT, have a low recurrence risk. 
Methods: Brazilian tertiary hospital cohort was followed for an average of 
30 months after anticoagulation withdrawal for a first VT. Patients with 
indication for indefinite anticoagulation were not included. The primary end 
point was objective recurrent VT. 
Results: Recurrent VT was recorded in 7% of 378 eligible patients. Patients 
with a provoked first event and positive past risk situations for VT had an 
incidence rate of recurrence of 1.16 (95% confidence interval [CI], 0.47-2.39) 
per 100 patient-years. The incidence rate ratio (IRR) of this subgroup compared 
to patients with a provoked event without other past risk situations for VT was 
1.1 (95% CI, 0.3-4.4). This IRR was 3.3 (95% CI, 1.3-8.7) in patients with an 
unprovoked event and positive past risk situations and 5.1 (95% CI, 1.6-16.1) in 
patients with an unprovoked event and no past risk situations.  
Conclusions: Asking a patient about past exposure of venous thrombosis 
risk factors long before the occurrence of a first venous thrombosis occurred, 
does not provide information to classify patients at lower risk for recurrence 




Venous thrombosis is a disease that occurs in approximately 1-2 per 1000 
persons per year [1]. Despite adequate treatment, up to one quarter of 
patients with venous thrombosis will experience a recurrent event within the 
subsequent 5 years [2]. It has been recognized that the presence of a transient 
or reversible provoked risk factor at the time of venous thrombosis is 
associated with a decreased risk of recurrence after anticoagulant therapy is 
stopped [3]. Therefore, a relatively short period of anticoagulant treatment 
with vitamin K antagonists is advised for those with clear provoking risk 
factors for venous thrombosis [4]. However, because a substantial number of 
recurrent events occur without a clear provoking risk factor, many patients 
may need indefinite anticoagulant treatment after a first event occurred, that 
may lead to serious side effects such as major bleeding [5]. The challenge 
therefore is to identify other patient groups that may also have a low risk of 
recurrence and could receive anticoagulants for a fixed (short) time. 
The thrombosis potential model takes into consideration that the thrombosis 
potential will drop sharply after the occurrence of a provoked event and that 
such an individual will not readily cross the thrombosis threshold again, 
consequently leading to a reduced risk for recurrence [6,7]. Considering this 
model we hypothesized that patients at risk for recurrent venous thrombosis, 
who had experienced transient provoked risk factors previously, yet not 
developed thrombosis at that time, would have a lower risk of recurrence in 
comparison with those whose first (provoked or unprovoked) event was not 
preceded by provoked risk factors. To study this, we analyzed a cohort of 
378 patients who were questioned about past risk situations for venous 
thrombosis, yet not related to an episode of thrombosis at that time.   
Past provoking venous thrombosis risk situations 




Subjects consisted of patients with one previous venous thrombotic event that 
were all seen by the same clinician (i.e. DDR) from April 2000 to September 
2010 at the University Hospital of Federal University of Minas Gerais, Belo 
Horizonte, Brazil. Patients were referred from anywhere in the State of Minas 
Gerais by their doctors who looked after them during the first episode of 
venous thrombosis. There was no control over these referrals, they were 
included consecutively, but certainly they were not consecutive patients with 
thrombosis in the state. Throughout the study, patients’ data were collected in 
a standardized method by using a form with questions related to first and 
recurrent venous thrombosis. A total of 786 patients who were diagnosed 
elsewhere with previous deep vein thrombosis (DVT) and/or pulmonary 
embolism (PE) were attended at the outpatients’ clinic (Figure 1). We 
excluded 52 patients due to the absence of an objectively confirmatory test for 
first PE or DVT. Due to possible differences in the hemostatic system, patients 
younger than 16 years old were also excluded (N = 10). Other patients were 
excluded due to their high risk for recurrence: more than 1 previous episode of 
thrombosis (N = 35), presence of systemic lupus erythematosus or 
antiphospholipid syndrome (N = 75), sickle cell anemia (N = 1); diagnosis of 
cancer at the time of inclusion or within 6 months after the first venous 
thrombosis, homozygosity/double heterozygosity state for factor V Leiden or 
prothrombin G20210A, or antithrombin deficiency (N = 21). Therefore, these 
patients received indefinite treatment with oral vitamin K antagonists. Another 
32 patients were also excluded because they had either another reason (atrial 
fibrillation, for example), or the wish to maintain use of anticoagulation 
indefinitely. Patients without an objectively confirmed recurrence were 
excluded (N = 138), and 2 patients died before enrollment. Despite efforts to 
follow-up all included patients, 42 patients (10%) were only seen at the time of 
enrollment and not afterwards. These patients were excluded from the 
analysis, which resulted from the study of 378 patients. Seventy five percent 
of the patients were seen after 2005, reflecting the growth curve of the 
outpatients’ clinic. Patients were followed every 6 months either by phone call 
or by attending the clinic. Patients were not systematically screened with 
ultrasonography since we were only interested in symptomatic recurrent 
venous thrombosis. A standardized questionnaire was completed by a 
professional healthcare assistant. The study ended in November 2010. At that 
time we had full information of 343 patients (91%). Among the other 35 (9%) 
patients who were not re-interviewed after January 1st 2010, 14 were evaluated 
in 2009, and some of these patients had already completed the follow up 
period due to recurrence of venous thrombosis (N = 2). The definition of 
follow-up time is described in the “statistical analysis” heading. All patients 
were advised to seek the outpatients’ clinic in case of suspected DVT or PE. 
All eligible patients for this study provided written informed consent, and the 




The duration of anticoagulation for provoked venous thrombosis was 3-6 
months and for unprovoked venous thrombosis 6-12 months. Some patients 
were treated with anticoagulants for longer or shorter time duration mainly 
because of individual patient preferences. 
The first episode of venous thrombosis was considered established if 
proximal DVT was confirmed by compression ultrasound, and PE by 
ventilation/perfusion lung scanning or spiral computer tomography scanning. 
Recurrence was considered established if it was demonstrated by objective 
techniques at another site than the first event, or at the same site if previously 
repeated tests showed no residual venous thrombosis. If the recurrence of 
DVT was at the same site and we had not previously repeated tests to 
analyze if there was residual venous thrombosis, we only considered 
recurrence when the compressive ultrasound (CUS) showed new thrombus 
formation together with clinical symptoms that were absent previously. Only 
the objectively demonstrated PE was considered a recurrence. If these 
criteria were not fulfilled, anticoagulant treatment was withheld and the 
event was not classified as a recurrent venous thrombosis.  
Venous thrombosis (either first or recurrent) was defined as provoked if it 
had occurred at or within 3 months after exposure to exogenous risk factors 
including surgery (with more than 30 minutes of duration), trauma leading to 
hospitalization, immobilization for more than 3 days (hospitalization for 
clinical reasons), limb immobilization in a plaster cast for more than 7 days, 
pregnancy, post-delivery period (2 months), the use of oral contraceptives or 
hormonal replacement therapy (at the time of  thrombosis), presence of 
autoimmune diseases, or active malignancy. In the absence of these risk 
factors, venous thrombosis was classified as unprovoked.  
During the medical visit, patients were asked about past risk situations for 
thrombosis at any time of life. The questions were related to use of oral 
contraceptives or hormonal replacement therapy, pregnancies, surgeries, 
immobilization with plaster cast in the lower limbs or any hospital admission 
for clinical reasons for more than 3 days. If they answered positive on any of 
these risk situations that occurred at least 3 months or more before the event 
occurred, they were considered as positive for past risk situations for venous 
thrombosis. Patients were submitted to CUS or ventilation/perfusion lung 
scanning or spiral computer tomography scanning around the end of 
anticoagulation use, and were separated in two groups: those with complete 
recanalization and those with incomplete or absent recanalization, according 
to the result of the image test. A family history was considered positive 
when the patient had one or more first degree relatives (parents, sibling 
and/or offspring) with venous thrombosis documented by image tests and/or 
with history of vitamin K antagonist use due to venous thrombosis.    
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Statistical	  analysis	   	  
Observation time started after vitamin K antagonists were withdrawn and 
ended at time of recurrence or at the last consultation. Incidence rates of 
recurrent thrombotic events were calculated as the number of events over the 
accumulated observation time. Incidences and 95% confidence intervals 
(95% CI) were calculated under the Poisson distribution assumption. 
Stratified analyses were used to assess the risk of thrombotic events 
recurrence by sex, idiopathic or provoked classification of first thrombotic 
event, status of image test around the end of anticoagulation (recanalization), 
presence or absence of family history of venous thrombosis and presence or 
absence of past risk situations for venous thrombosis. The presence of a 
triggering factor was evaluated together with past risk situations status and 
sex. The risk of recurrence in patients with unprovoked venous thrombosis 
was assessed by age at first event.   
Including patient time before patients were enrolled could be problematic as 
this may create a survivor bias [8]. Therefore, we performed a sensitivity 
analysis in which observation time started at enrollment (and when vitamin 
K antagonists were withdrawn) and ended at time of recurrence or last 
consultation (model A). Another type of bias may arise when follow-up time 
is not ended on a specified date, because subjects may have a reason not to 
return to the clinic or answer a telephone call. Therefore, we performed a 
second sensitivity analysis in which follow-up time started when vitamin K 
antagonists were withdrawn and ended at time of recurrence or January 1st 
2010, whichever occurred first (model B). Some patients did not use vitamin 
K antagonists at time of enrollment and model B allowed that observation 
time defined by “date of enrollment - date of withdrawing vitamin K 
antagonists” to be included. This is different from model C where the 
follow-up time started at time of enrollment (and when vitamin K 
antagonists were withdrawn) and ended at time of recurrence or January 1st 
2010, whichever occurred first.   
Further subgroup analyses such as distinction between major provoking risk 
factors (surgery.) and minor provoking risk factors (contraception, or type of 
contraception, pregnancy) or an interaction analysis on age and other 
covariates such as sex were not performed since our study was too small to 
yield meaningful results. 
Statistical analyses were performed using SPSS software, version 16.0 




The study cohort included 378 patients, clinical characteristics are shown in 
Table 1. Of patients, 291 (77%) were female, 253 (67%) had a provoked 
venous thrombosis, the median age at time of the first event was 36 years, 
109 (29%) had a distal venous thrombosis, 175 (46%) had a proximal venous 
thrombosis, 71 (19%) had a PE and 22 (6%) had DVT and PE together 
(these patients were analyzed in the PE group). Oral contraceptives, 
hormone replacement therapy, pregnancy or postpartum period were the 
most prevalent provoked risk factors appearing 189 times (in 65% of the 
female population). Ultrasound/duplex was the diagnostic image method in 
284 (75%) patients, ventilation/perfusion lung scan in 54 (14%) patients and 
spiral computer tomography scanning in 40 (11%) patients. A positive 
family history was present in 95 (25%) and positive past risk situations were 
present in 251 (66%) patients. The median time of anticoagulation, time 
between the end of anticoagulation and recurrence, interval between venous 
thrombosis, and of follow up were 8, 26, 42 months and 30 months, 
respectively. Recurrent venous thrombosis occurred in 25 (7%) patients. The 
median age at recurrence was 51 years. At a median of 7 months after their 
initial first event, patients were consulted by DDR.  
Patients with a provoked first event and positive past risk situations (> 
3months before the occurrence of a first venous thrombosis occurred) had an 
incidence rate of recurrence of 1.16 (95% CI, 0.47-2.39) per 100 patient-
years (Table 2). The incidence rate ratio of patients with a provoked event 
without other past risk situations for venous thrombosis compared to patients 
with a provoked first event and positive past risk situations was 1.1 (95% CI 
0.3-4.4). This incidence rate ratio was 3.3 (95% CI, 1.3-8.7) in patients with 
an unprovoked event and positive past risk situations and 5.1 (95% CI, 1.6-
16.1) in patients with an unprovoked event and no past risk situations versus 
patients with a provoked first event and positive past risk situations. 
Sensitivity analyses taking period of follow up into account showed similar 
findings; i.e. previous risk situations mildly affected recurrent venous 
thrombosis risk.   
In Table 3 it is shown that male sex was associated with an increased risk for 
recurrence (incidence rate ratio 3.8; 95% CI, 1.7-8.4), as was unprovoked 
first venous thrombosis (incidence rate ratio, 3.6; 95% CI, 1.6-7.9), and also 
residual vein thrombosis (incidence rate ratio, 3.1; 95% CI, 0.9-10.7). 
Patients with a positive family history had an incidence rate ratio for 
recurrence of 1.3 (95% CI, 0.5-3.0) compared to patients with a negative 
family history of venous thrombosis. Patients aged >40 with an unprovoked 
first event had an incidence rate ratio of 1.0 (95% CI, 0.3-2.9) for recurrence 
compared to patients aged <40 with an unprovoked first event.  
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Because the risk of recurrence in men compared to women may partly be 
explained by provoking hormonal factors [9], we performed another 
subgroup analysis in Table 4 wherein the first event type (unprovoked or 
provoked) was taken into account. Women experienced a provoked first 
event at a median age of 32 years; their incidence rate of recurrence was 0.97 
(95% CI, 0.42-1.91) per 100 patient-years. Women with an unprovoked first 
event had a median age of 46 years; their risk of recurrence was 2.8 (95% 
CI, 0.9-8.5) fold increased compared to women with a first provoked event. 
Men with a provoked first event had a median age of 38 years and had a 3.4 
(95% CI, 0.7-15.9) fold increased risk compared to women with provoked 
first venous thrombosis, while men with an unprovoked first event had a 
median age of 42 years and a 5.5 (95% CI, 2.1-13.4) fold increased risk of 
recurrence.  Sensitivity analyses, in which differences in follow-up time 




This cohort study showed, in agreement with other studies, that patients with 
first provoked venous thrombosis have a 2-3 fold lower risk for a recurrence 
than those with unprovoked events [10,11]. Risk situations for venous 
thrombosis that occurred in the past yet did not result in venous thrombosis 
at that time were noted in 66% of patients. Although the high rate of positive 
responders to this question provided a large group that, according to our 
hypothesis, could also be at lower risk for recurrence compared to those who 
experienced their first event without ever having had a venous thrombotic 
risk situation, their risk was still 3-fold higher than those who had a 
provoked risk factor present at time of first venous thrombosis. Hence, 
asking patients with venous thrombosis about risk situations for venous 
thrombosis that took place long before their first thrombotic event occurred 
seems to be of little value for predicting if an individual patient is at low risk 
for recurrence.  
The young age of patients enrolled in our study (median age 36 years) 
clearly shows that the cohort does not represent a normal distribution of 
patients with first venous thrombosis, as the median age at onset of a first 
venous thrombotic event in the community is 62 years [12]. To test whether 
selection bias influenced our relative risk estimates, we created subgroups 
that made it able to compare whether our results are similar to cohorts that 
included consecutive patients from normal populations [2,3]. It turned out 
that these risk estimates were similar to normal populations. We did find, as 
other studies, that the risk of recurrent venous thrombosis is approximately 
3-4 times higher in men compared to women [13,14]. Some studies 
suggested that the lower risk of recurrent venous thrombosis in women can 
be explained by hormonal risk factors [9,15]. This also appeared partly to be 
the case in our study where women with a first provoked event had a very 
low absolute risk for recurrence. Nevertheless, when we compared women 
who had an unprovoked first event to men, men still had an increased risk 
for recurrence, as has also been observed in other studies [13]. Whether 
residual vein thrombosis increases the risk of recurrence has not been studied 
extensively, but seems to be a risk factor for recurrence [16]. This finding 
was confirmed in our study although it had broad confidence intervals 
(incidence rate ratio 3.1; 95% CI, 0.9-10.7). Therefore, it should be treated 
with caution. Nevertheless, the point estimate is quite similar to a much 
larger study (N= 538) on this issue that was performed in a more 
generalizable cohort than ours [16,17]. Furthermore, age an important risk 
factor for a first episode of venous thrombosis, seemed to play a little role in 
the risk of recurrence, as was also observed in other studies [13,18]. 
Although consistent with other reports, this finding should be interpreted 
with caution as our cohort was composed of young patients who may have a 
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different risk for recurrence than older patients with venous thrombosis. Not 
many studies have reported on positive family history as a risk factor for 
recurrence, but the few that did report no influence on recurrence risk [19]. 
This is also in agreement with our findings. Because the subgroup analyses 
performed in this study revealed similar findings to normal population 
studies, this added strength that the main outcome in the present study (i.e. 
that past venous thrombosis risk situations only slightly influences recurrent 
venous thrombosis risk) also accounts to normal populations. 
Some other methodological aspects of our study warrant further comments. 
First, although the absolute risk for recurrence was high in our study (3 per 
100 person years), it is similar to absolute risks for recurrence found in the 
community [11,13]. Second, our total event rate for recurrence was low (N = 
25), making it difficult to adjust our data with Cox proportional hazard 
models. However, stratified analysis demonstrated results that were in 
agreement with the literature. Third, many patients were excluded from the 
study because they did not have an image test confirming the first event or the 
possible recurrence. Indeed, studies have shown that a diagnosis of either first 
or recurrent venous thrombosis based only on clinical approach is not 
considered the state of the art practice, given the large number of false positive 
diagnosed venous events [20,21]. Fourth, an interesting question that our study 
could not analyze due to small numbers is whether prolonged periods with 
vitamin K antagonists result in an overall decreased risk of recurrent venous 
thrombosis after anticoagulation is withdrawn. However, a randomized study 
on this issue previously showed that  although patients on vitamin K 
antagonists have a low risk for recurrence, the risk reappears as soon as 
anticoagulation is stopped [22]. Finally, patients with distal vein thrombosis 
were included although they seem to have a lower probability for recurrence 
[23,24]. Small numbers did not enable us to exclude these patients.  
In conclusion, in this study the risk for recurrence was related with the nature 
of a first provoked or unprovoked event and only slightly with the presence of 
other past risk situations for venous thrombosis. Asking a patient about past 
exposure of venous thrombosis risk factors long before the occurrence of a 
first venous thrombosis occurred, does not provide information to classify 
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Table 1: Demographics characteristics
Patients N (%)
Sex Female Male Total
291 (77) 87 (23) 378 (100)
Risk Factors Yes No Missing
253 (67) 122 (32) 3 (1)
Number of risk factors at the time of VT One Two Three Total
253 (83) 46 (15) 7 (2) 306 (100)
Type of risk factors (all patients):
Surgery 48 (16)
Imobilization 39 (13)
Oral contraceptive 139 (45)
Hormone replacement therapy 14 (5)
Pregnancy or postpartum period 36 (12)
Autoimune diseases 9 (3)
Neoplasia or chemotherapy 13 (4)
Others 8 (3)
VT Place Proximal DVT Distal DVT PE/DVT Missing
175 (46) 109 (29) 93 (24.7) 1 (0.3)
Diagnostic method Ultrasound/duplex V/P Lung Scan Angio CT
284 (75) 54 (14) 40 (11)
Mean (Years) Median (Years)
Age first event 40 36
Age at recurrence 51 51
Mean (Months) Median (Months)
Anticoagulation Period 13 8
Time between the end of VKA and recurrence 29 26
Time between VTs 40 42
Follow up 40 30
Yes No Unknown Missing
Family History of VT 95 (25) 275 (73) 5 (1.2) 3 (0.8)
Recurrence 25 (7) 353 (93)
Risk factors for recurrence 5 (20) 20 (80)
Recurrence place Proximal DVT Distal DVT PE Both
10 (40) 10 (40) 4 (16) 1 (4)
Recanalization Absent Incomplete Complete Missing
4 (1) 187 (49) 131 (35) 56 (15)
Past history of risk situations Yes No Missing
251 (66) 105 (28) 22 (6)
VKA denotes, vitamin K antagonist; VT, venous thrombosis; DVT, deep venous thrombosis; 
PE, pulmonary embolism; CT, computer tomography; V/P, ventilation/perfusion.
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Figure 1: Flow diagram of the study cohort.
786 Patients assessed for venous thromboembolism (PE or DVT)
First event without confirmatory test (n=52)
Younger than 16 years (n=10)
More than one VTE before the first consultation (n=35)
Systemic lupus erythematosus and/or 
antiphospholipid syndrome (n=75)
Sickle cell anemia (n=1) 
FV Leiden in homozygous, double heterozygous,
 antithrombin deficiency or neoplasia (n=21)
Indefinite use of vitamin K antagonist  (n=32)
Death before the inclusion (n=2)
Clinical recurrence without confirmatory test (n=138)
420 Patients eligible
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ABSTRACT	  
Objective: Strategies targeting at classifying the risk for recurrent venous 
thrombosis (VT) are needed. We previously hypothesized, by studying a 
cohort of patients, that those who had ‘survived’ risk situations for VT 
without developing it would, after a first VT, have a low recurrence risk. 
Therefore, we re-evaluated the same cohort, now with a longer follow-up. 
Methods: Patients, after a first confirmed VT event, were followed for an 
average of 43 months after suspension of anticoagulation. Patients with 
indication for indefinite anticoagulation were not included. The primary end 
point was objective recurrent VT. 
Results: Recurrent VT was recorded in 9% of 378 eligible patients. Patients 
with a provoked first event and positive past risk situations for VT had an 
incidence rate of recurrence of 1.26 (95% CI, 0.60-2.31) per 100 patient-years. 
The incidence rate ratio (IRR) of this subgroup compared to patients with a 
provoked event without other past risk situations for VT was 0.8 (95% CI 0.2-
2.9). This IRR was 2.8 (95% CI, 1.2-6.5) in patients with an unprovoked event 
and positive past risk situations and 7.1 (95% CI, 3.0-17.1) in patients with an 
unprovoked event and no past risk situations. When only idiopathic first 
events were evaluated the IRR was 2.5 (95% CI, 1.1-5.9) for patients without 
past risk situation compared with those with these history.  
Conclusions: In this study asking a patient about past exposure to risk 
factors for VT long before the occurrence of a first VT occurred, could be 
used to classify patients with a first unprovoked VT at higher risk for 




Venous thrombosis (VT) occurs in 1-2 per 1000 persons per year [1]. 
Approximately 30% of patients with VT will experience a recurrent event 
within the subsequent 5 years [2]. It has been recognized that the presence of 
a transient or reversible risk factor at the time of VT is associated with a 
decreased risk of recurrence after anticoagulant therapy is stopped [3]. 
Therefore, a relatively short period of anticoagulant treatment with vitamin 
K antagonists is advised for those patients [4]. However, because about 50% 
of events occur without a clear provoking risk factor, many patients may 
need long-term or even indefinite anticoagulation after the occurrence of a 
first event. This treatment may lead to serious side effects such as major 
bleeding [5]. Therefore, the challenge is to identify new subgroups of 
patients with unprovoked VT who have a low rather than high risk of 
recurrence. This would allow shortening the duration of the anticoagulant 
treatment in these patients. 
The thrombosis potential model takes into consideration that the thrombosis 
potential will drop sharply after the occurrence of a provoked event and that 
such an individual will not readily cross the thrombosis threshold again, 
consequently leading to a reduced risk for recurrence [6,7]. Considering this 
model, we previously hypothesized that those who had ‘survived’ many risk 
situations without developing VT would, after a first VT, have a low 
recurrence risk [8]. We observed that the risk for recurrence seemed related 
with the presence of past risk situations for VT, but as our total event rate for 
recurrence was low (N=25) and our follow up was relatively short, we could 
not rule out a possible chance finding. For this reason, we re-evaluated the 
same cohort of 378 patients, now with a median follow-up of 13 more months.  
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METHODS	  
The subjects of the cohort were described previously [8]. The study started 
in April 2000. Patients were seen in our outpatients’ clinic (Hematology 
Unit, University Hospital, Universidade Federal de Minas Gerais, Belo 
Horizonte) or contacted by phone at least once a year. All but 62 patients 
were contacted by phone or had a clinical evaluation at July 1st 2011. 
Patients were not systematically screened with ultrasonography since we 
were only interested in symptomatic recurrent VT. All patients were advised 
to seek the outpatients’ clinic in case of suspected DVT or PE. A 
standardized questionnaire with study questions was completed by a 
professional healthcare assistant in each patient visit. All eligible patients for 
this study provided written informed consent, and the study was approved by 
the local ethics committees.  
 
Definitions	  
The duration of anticoagulation for provoked VT was 3-6 months and for 
unprovoked VT 6-12 months. Some patients were treated with anticoagulants 
for longer or shorter time duration mainly because of individual patient 
preferences. The first episode of VT was considered established if proximal 
DVT was confirmed by compression ultrasound, and PE by 
ventilation/perfusion lung scanning or spiral computer tomography scanning. 
Recurrence was considered established if it was demonstrated by objective 
techniques at another site than the first event, or at the same site if previously 
repeated tests showed no residual VT. If the recurrence of DVT was at the 
same site and we had not previously repeated tests to analyze if there was 
residual VT, we only considered recurrence when the compressive ultrasound 
(CUS) showed new thrombus formation in combination with clinical 
symptoms that were absent previously. Only the objectively demonstrated PE 
was considered a recurrence. If these criteria were not fulfilled, anticoagulant 
treatment was withheld and the event was not classified as a recurrent VT. VT 
(either first or recurrent) was defined as provoked if it had occurred at or 
within 3 months after exposure to exogenous risk factors including surgery 
(with more than 30 minutes of duration), trauma leading to hospitalization, 
immobilization for more than 3 days (hospitalization for clinical reasons), limb 
immobilization in a plaster cast for more than 7 days, pregnancy, puerperium 
(until 2 months after delivery), use of oral contraceptives or hormonal 
replacement therapy (at the time of  thrombosis), presence of autoimmune 
diseases, or active malignancy. In the absence of these risk factors, VT was 
classified as unprovoked. 
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During the medical visit, patients were asked about past risk situations for 
VT at any time of life. The questions were related to use of oral 
contraceptives or hormonal replacement therapy, pregnancies, surgeries, 
immobilization with plaster cast in the lower limbs or any hospital admission 
for clinical reasons for more than 3 days. If they answered positive on any of 
these risk situations that occurred at least 3 months or more before the event 
occurred, they were considered as positive for past risk situations for VT. 
Patients were submitted to CUS or ventilation/perfusion lung scanning or 
spiral computer tomography scanning around the end of anticoagulation use, 
and were separated in two groups: those with complete recanalization and 
those with incomplete or absent recanalization, according to the result of the 
image test. A family history was considered positive when the patient had 
one or more first degree relatives (parents, sibling and/or offspring) with VT 
documented by image tests and/or with history of vitamin K antagonist use 
due to VT. Follow up period started after vitamin K antagonist were 
withdrawn and finished at 01.07.2011 or last consultation or death, 
whichever occurred first.  
 
Statistical	  analysis	  
Observation time started after vitamin K antagonists were withdrawn and 
ended at the time of the recurrence or at the last consultation. Incidence rates 
of recurrent thrombotic events were calculated as the number of events over 
the accumulated observation time. Incidences and 95% confidence intervals 
(95% CI) were calculated under the Poisson distribution assumption. 
Stratified analyses were used to assess the risk of thrombotic events 
recurrence by age, sex, idiopathic or provoked first thrombotic event, status 
of image test around the end of anticoagulation (recanalization), family 
history of VT and presence or absence of past risk situations for VT. 
Including patient time before patients were enrolled (i.e. patients who 
stopped anticoagulant treatment before the first appointment with the 
researcher) could be problematic as this may create a survivor bias [9]. 
Therefore, we performed 3 sensitivity analyses to take observation time into 
close account (Figure 1). Statistical analyses were performed using SPSS 
software, version 17.0 (SPSS Inc., Chicago ILL). 
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RESULTS	  
The study cohort comprised 378 patients: 291 (77%) were female, 253 
(67%) had a provoked VT, the median age at time of the first event was 36 
years, 109 (29%) had a distal VT, 175 (46%) had a proximal VT, 71 (19%) 
had a PE and 22 (6%) had DVT and PE together (these patients were 
analyzed in the PE group). Oral contraceptives, hormone replacement 
therapy, pregnancy or puerperium were the most prevalent provoked risk 
factors appearing 189 times (in 65% of the female population). 
Ultrasound/duplex was the diagnostic image method in 284 (75%) patients, 
ventilation/perfusion lung scan in 54 (14%) patients and spiral computer 
tomography scanning in 40 (11%) patients. Family history for VT was 
present in 95 patients (25%) and positive past risk situations (patients who 
experience a well-known risk situation for VT in the past and did not 
develop thrombosis at that moment) were present in 251 patients (66%). 
Recurrent VT occurred in 35 patients (9%), trigger factors were present in 6 
(17%) patients and the thrombotic event was unprovoked in 29 (83%). The 
median age at recurrence was 49 years. At a median of 7 months after their 
initial first event, patients were consulted by the researcher. Only two 
patients died during the follow up and the causes were unknown. The 
median follow-up time was 43 months. 
Patients with a provoked first event and positive past risk situations had an 
incidence rate of recurrence of 1.26 (95% CI, 0.60-2.31) per 100 patient-
years (Table 1). The incidence rate ratio of patients with a provoked event 
without other past risk situations for VT compared to patients with a 
provoked first event and positive past risk situations was 0.8 (95% CI 0.2-
2.9). This incidence rate ratio was 2.8 (95% CI, 1.2-6.5) in patients with an 
unprovoked event and positive past risk situations and 7.1 (95% CI, 3.0-
17.1) in patients with an unprovoked event and no past risk situations versus 
patients with a provoked first event and positive past risk situations. The 
incidence rate ratio was 2.5 (95% CI, 1.1-5.9) for patients without past risk 
situation compared with those with these history when only idiopathic first 
events were evaluated. Sensitivity analyses taking period of follow up into 
account showed similar findings; i.e. previous risk situations affected 
recurrent VT risk only in patients with unprovoked first event.   
Male sex was associated with an increased risk for recurrence (incidence rate 
ratio 5.5; 95% CI, 2.8-10.8), as was unprovoked first VT (incidence rate 
ratio, 4.1; 95% CI, 2.1-8.1). Residual vein thrombosis was a risk factor for 
recurrence (incidence rate ratio, 2.2; 95% CI, 0.9-5.4), although presented 
broad confidence intervals (Table 2). Patients with a positive family history 
had an incidence rate ratio for recurrence of 1.3 (95% CI, 0.6-2.6) compared 
with patients with a negative family history of VT. Patients older than 40 
years with an unprovoked first event had an incidence rate ratio of 0.9 (95% 
CI, 0.4-2.1) for recurrence compared with patients younger than 40 with an 




We have re-evaluated a cohort of 378 patients with a first confirmed VT 
event for recurrent VT and concluded that previous risk situations for VT 
affected recurrence risk only in patients with an unprovoked first event. To 
our knowledge, this is the first approach to explore past risk situations as a 
risk factor for VT. 
This incidence rate ratio for recurrence was 2.8 in patients with an 
unprovoked event and positive past risk situations and 7.1 in patients with an 
unprovoked event and no past risk situations when compared with patients 
with a provoked first event and positive past risk situations. Thus, collecting 
information about risk situations for VT that took place long before the 
occurrence of a first thrombotic event seems to add information about the 
risk for recurrence when the event was unprovoked. 
Results from this cohort study are in agreement with other studies, in which 
patients with first provoked VT have a lower risk of recurrence than those 
with unprovoked events [10,11]. Risk situations for VT that occurred in the 
past yet did not result in VT at that time were noted in 66% of patients. The 
high rate of positive responders to this question provided a large group that, 
according to our hypothesis, could also be at lower risk of recurrence 
compared to those who experienced their first event without ever having had 
a venous thrombotic risk situation. However, we could only observe this 
when the first event was unprovoked.  
The young age of patients enrolled in our study (median age 36 years) 
clearly shows that the cohort does not represent a normal distribution of 
patients with first VT, as the median age at onset of a first venous thrombotic 
event in the community is 62 years [12]. To test whether selection bias 
influenced our relative risk estimates, we created subgroups to compare 
whether our results are similar to cohorts that included consecutive patients 
from normal populations [2,3]. It turned out that these risk estimates were 
similar to those of general populations.  
In our study, we also found that the risk of recurrent VT was higher in men 
than in women, as has been shown by others [13,14]. Furthermore, age an 
important risk factor for a first episode of VT, was not a risk factor for 
recurrence in this study. This has also been reported by other studies [13,15]. 
Residual vein thrombosis seems to be a risk factor for recurrence [16]. This 
finding was confirmed in our study although it had broad confidence interval 
(incidence rate ratio 2.2; 95% CI, 0.9-5.4). Nevertheless, the point estimate 
is similar to a larger study (n= 538) that also explored this question [16,17]. 
Even though, the difficulty in the standardization of residual thrombosis is 
always a problem in these studies and our study.  
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Few studies have reported on positive family history as a risk factor for 
recurrence, but the few that did report no influence on recurrence risk [18]. 
This is also in agreement with our findings.  
Some methodological aspects of our study warrant further comments. First, 
although the absolute risk of VT recurrence was high in our study (2.09 per 
100 person years), it is similar to absolute risks of recurrence found in the 
community [11,13]. Second, as the total number of recurrences was low 
(n=35), it was difficult to carry out a multivariate analysis. However, 
stratified analysis demonstrated results that were in agreement with the 
literature. Third, patients with distal vein thrombosis were included in this 
study although they seem to have a lower probability of recurrence [19,20]. 
Finally, because the subgroup analyses performed in this study revealed 
similar findings to general population studies, we believe that the main 
results of the present study (i.e. that past VT risk situations decrease 
recurrent VT risk) are generalizable to other cohorts. Nevertheless, at least 
one other cohort study should confirm our findings before implications from 
a clinical level can be inferred from our findings, and such study should also 
include patients more representative for a general population. 
In conclusion, in this study asking a patient about past exposure to risk 
factors for VT long before the occurrence of a first VT occurred, could be 
used to classify patients with a first unprovoked VT at higher risk for 
recurrence of VT.      
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The sensitivity analysis was aimed to take observation time into account. In 
model A, observation time started at enrollment (and when vitamin K 
antagonists were withdrawn) and ended at time of recurrence or last 
appointment. In model B, the follow-up time started when vitamin K 
antagonists were withdrawn and ended at the time of recurrence or July 1st 
2011, whichever occurred first. In model C the follow-up time started at the 
time of enrollment (and when vitamin K antagonists were withdrawn) and 
ended at the time of recurrence or July 1st 2011, whichever occurred first. 
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Venous thrombosis (VT) is a disease that occurs in approximately 1-2 per 
1000 persons per year [1]. Despite an appropriate treatment, up to one 
quarter of patients with VT will experience a recurrent event within the 
subsequent 5 years [2]. It has been recognized that the presence of a transient 
or reversible provoked risk factor at the time of VT is associated with a 
decreased risk of recurrence after stopping anticoagulant therapy [3]. 
Therefore, a relatively short period of anticoagulant treatment with vitamin 
K antagonists is advised for those with clear provoking risk factors for VT, 
such as oral contraceptive use, hospitalization, or surgery [4]. However, 
approximately 30%-50% of events occur without association with a 
provoking risk factor. Since the risk for recurrent VT is higher when the first 
event is unprovoked, such patients may need indefinite anticoagulant 
treatment. This approach could, however, lead to major side effects such as 
severe bleeding [5]. The challenge, therefore, is to identify patient groups 
who suffered an unprovoked event and still have a low risk of recurrence. 
These patients might benefit of anticoagulants for a fixed (shorter) time. 
Since prothrombotic alterations can be demonstrated in at least 50% of 
patients with VT [6], testing patients with a first VT has gained great 
interest. Potential advances of testing patients might be the chance to 
elucidate the cause of the thrombosis and to track unaffected family 
members. However, there are also potential disadvantages. Although the 
presence of prothrombotic alterations is currently considered a weak 
predictor of recurrence in patients with a first episode of VT, [3,7,8] these 
results were mostly obtained in patients with either provoked and 
unprovoked first VT. Whether prothrombotic alterations have a predictive 
value for recurrence in patients who had a first unprovoked event is less well 
studied. Furthermore, most studies that were published on this issue [7,9], 
measured prothrombotic laboratory abnormalities (such as levels of factor 
VIII or homocysteine) only once, increasing the chance of a false positive 
(high) value and dilution of risk estimates.   
We performed a prospective cohort study to assess the risk of recurrence in 
patients with provoked and unprovoked first VT, related to the presence or 
absence of prothrombotic alterations. In addition, these abnormalities were 
only considered present when they were confirmed in at least two 
consecutive measurements. 
The subjects of the cohort and definitions of the study were described 
previously [10]. Briefly, subjects were patients with one previous venous 
thrombotic event followed from April 2000 to July 2011 at the University 
Hospital of Universidade Federal de Minas Gerais and at Hematológica, a 
specialized medical center in Hematology, Belo Horizonte, Brazil. All 
patients were attended by the same clinician (i.e. DDR) Patients were 
referred from anywhere in the State of Minas Gerais by their doctors who 
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looked after them during the first episode of VT. There was no control over 
these referrals. Patients were included consecutively, but certainly they were 
not consecutive patients with thrombosis in the State. Throughout the study, 
patients’ data were collected using a standardized form with questions 
related to first and recurrent VT. Venous thrombosis (either first or 
recurrent) was defined as provoked if it had occurred at or within 3 months 
after exposure to exogenous risk factors including surgery (with more than 
30 minutes of duration), trauma leading to hospitalization, immobilization 
for more than 3 days (hospitalization for clinical reasons), limb 
immobilization in a plaster cast for more than 7 days, pregnancy, post-
delivery period (2 months), the use of oral contraceptives or hormonal 
replacement therapy (at the time of  thrombosis), presence of autoimmune 
diseases, or active malignancy. In the absence of these risk factors, venous 
thrombosis was classified as unprovoked. Despite efforts to follow-up all 
included patients, 42 patients (10%) were only seen at the time of enrolment. 
These patients were excluded from the analysis, which resulted in 378 
eligible patients. All but 62 patients who had incomplete follow-up (16%) 
were contacted by phone or had a clinical evaluation at July 1st 2011. The 
last consultation of the 62 patients with incomplete follow-up was between 
09.03.2005 and 30.03.2011 (2 in 2011, 41 in 2010, 7 in 2009, 5 in 2008, 5 in 
2007 and 1 in 2005). At that moment they were questioned about recurrent 
VT and included in the analysis up to this date. Recurrence was considered 
established if it was demonstrated by objective techniques at another site 
than the first event, or at the same site if previously repeated tests showed no 
residual venous thrombosis. If the recurrence of DVT was at the same site 
and we had not previously repeated tests to analyze if there was residual 
venous thrombosis, we only considered recurrence when the compressive 
ultrasound showed new thrombus formation together with clinical symptoms 
that were absent previously. Only the objectively demonstrated PE was 
considered a recurrence. If these criteria were not fulfilled, anticoagulant 
treatment was withheld and the event was not classified as a recurrent 
venous thrombosis. We had access to all discharge letters. Laboratory test 
information was available for factor VIII activity, homocysteine, factor V 
Leiden, (rs6025),  prothrombin G20210A (rs1799963) and blood group. We 
analysed these risk factors individually and grouped. We considered high 
factor VIII as levels > 150 IU/dL in two occasions after at least three months 
apart. Similarly a high level of homocysteine (> 20 µmol/L) was only 
considered when confirmed in a subsequent testing. All eligible patients for 
this study provided written informed consent, and the study was approved by 
the local ethical committee. Observation time started after vitamin K 
antagonists were withdrawn and ended at time of recurrence or at the last 
consultation. Incidence rates of recurrent thrombotic events were calculated 
as the number of events over the accumulated observation time in different 
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groups of patients with specific prothrombotic alterations. The incidence rate 
ratio was calculated and patients without prothrombotic alterations were 
considered as the reference group. Incidences and 95% confidence intervals 
(95% CI) were calculated under the Poisson distribution assumption.  
Statistical analyses were performed using SPSS software, version 17.0 
(SPSS Inc., Chicago ILL). 
The study cohort included 378 patients; 291 (77%) were women, 253 (67%) 
had a provoked VT, the median age at time of the first event was 36 years, 
109 (29%) had a distal VT, 175 (46%) had a proximal VT, 71 (19%) had a 
PE and 22 (6%) had DVT and PE (these patients were analyzed in the PE 
group). The total follow-up was 1573 person-years, for a median follow-up 
of 43 months. Recurrent VT occurred in 35 (9%) patients, for an incidence 
of 22 per 1000 person-years. The median age at recurrence was 49 years. At 
a median of 7 months after their initial first event, patients were consulted by 
one physician (DDR). Only two patients died during the follow up and the 
causes were not related to VT. In patients with elevated factor VIII, 5 (11%) 
out of 47 had a second event of VT. Recurrence was also identified in 1 
(8%) out of 13 with high levels of homocysteine. The presence of factor V 
Leiden or prothrombin 20210A mutation were associated with VT 
recurrence in 2 (5%) out of 37 and 3 (15%) out of 20, respectively. Among 
the 190 patients with blood group non O 19 (10%) had a second event of VT 
(Table 1). The broad confidence interval of some groups reflects the small 
numbers. Despite this, the relative risk estimates are approximately 1 for all 
comparisons showing no association between VT recurrence risk and 
prothrombotic laboratory abnormalities (Table 1). A stratified analysis 
showed no increase in the risk for VT recurrence by sex and for patients with 
a provoked first event. However, in patients with an unprovoked first event 
there was a 4-fold increase in the recurrence risk in those with abnormal 
prothrombotic tests, albeit again with wide confidence intervals.  
It has been suggested that the identification of prothrombotic abnormalities 
could lead to reduced VT recurrence due to changes in clinical management, 
such as prolongation of initial anticoagulant treatment or intensified 
prophylaxis during high-risk situations. However, no different recurrence 
risk was found when tested patients were compared with patients who were 
not tested [11]. Despite a slightly different study question, the presence of 
prothrombotic abnormalities did not increase the risk for recurrence in our 
study, corroborating the findings of Coppens et al and others [11]. However, 
these latter studies did not stratify on type of first event (if provoked or 
unprovoked). In the present study, we observed that patients with a first 
unprovoked event and prothrombotic abnormalities had a 4.4-fold increased 
risk of recurrence. Although numbers were small, and therefore a chance 
result cannot be ruled out, this finding can be supported by taking the 
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thrombosis potential model into account [12]. Unprovoked events are those 
events of which we do not know the underlying cause. However, there may 
be several reasons why patients with unprovoked thrombosis had their event. 
If these reasons were in some part transient, such as an infection [13], or a 
flare of inflammatory bowel disease [14], and in some part chronic (e.g., 
prothrombotic abnormalities), one would expect the risk of recurrence to be 
increased in patients with prothrombotic abnormalities. In this case, the 
thrombosis potential in the latter (chronic causes) is not altered after the first 
event, but the thrombosis potential in the former group (transient causes) 
significantly drops after the first event. These patients will have a lower risk 
for recurrence than those with lasting prothrombotic abnormalities [12].  
Our study has limitations including small sample size and the selection of 
referred patients, as our Hospital is a tertiary care center. Patients were on 
average nearly 30 years younger than the average age of first VT in the 
community [15]. In addition, only 0.5% of 378 patients died during follow-
up, but as 16% of patients were lost to follow up, it is likely that at least 
some of these patients died, possibly due to thrombosis. However, because 
thrombophilia is not associated with a reduced life expectancy in previous 
studies [16,17], it is not likely that mortality of patients who were lost to 
follow-up biased our results.  
We conclude from our study that thrombophilia testing in all patients with a 
first VT is neither clinically feasible nor useful. Future studies are required to 
further elucidate if patients with a first unprovoked event and a negative result 
for prothrombotic abnormalities are at reduced risk for VT recurrence and 
could, therefore, benefit from a shorter period of anticoagulant treatment. 
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Table 1: Risk for venous thrombosis recurrence in subgroups based on laboratory findings
Number Patients IR per 100 PY IRRatio




Normal 298(86) 27(8) 1.98 (1.31-2.88) Reference
Elevated (>150%) 47(14) 5(1) 2.82 (0.92-6.59) 1.4 (0.6-3.7)
Homocysteine
Normal 340(96) 31(9) 2.03 (1.38-2.88) Reference
Elevated (>20 mMol/L) 13(4) 1(0.3) 2.13 (0.05-11.85) 1.1 (0.1-7.7)
Factor V Leiden
Wild type 329(90) 31(9) 2.20 (1.50-3.13) Reference
Heterozygote 37(10) 2(0.5) 1.04 (0.13-3.76) 0.5 (0.1-2.0)
Protrombin mutation
Wild type 337(94) 29(8) 1.92 (1.29-2.76) Reference
Heterozygote 20(6) 3(0.8) 4.41 (0.91-12.89) 2.3 (0.7-7.5)
Blood group
O 71(27) 5(2) 1.62 (0.53-3.79) Reference
Non-O 190(73) 19(8) 2.27 (1.37-3.55) 1.4 (0.5-3.7)
All thrombophilia
No 52(19) 3(6) 1.31 (0.28-4.00) Reference
Any ‡ 224(81) 22(10) 2.27 (1.41-3.42) 1.6 (0.5-5.5)
‡ Presence of at least one of the following: high factor VIII or homocysteine, presence of factor V Leiden 
or prothrombin mutation and blood group non-O
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SUMMARY	  
Chapter 1 describes the outline of this thesis and the rationale to subdivide 
this thesis into two parts: risk factors for first venous thrombosis, and risk 
factors for recurrent venous thrombosis.   
 
Part	  I:	  Risk	  factors	  for	  first	  venous	  thrombosis	  
Chapter 2 describes the association between pneumonia and risk of venous 
thrombosis in a large population-based case-control study (MEGA study), 
and whether this risk was influenced by immobility or unhealthy lifestyle 
factors. Gene-environment interactions were also assessed (i.e., the 
combined effect of pneumonia and prothrombotic genes), as this association 
could be clinically relevant for targeted thromboprophylaxis. Odds ratios 
were calculated as estimates of the relative risk, and were adjusted for age 
and sex by logistic regression methods to take the matching into account. 
Subgroup analysis involved stratification of patients with deep vein 
thrombosis of the leg only, or with pulmonary embolism with or without 
diagnosed deep vein thrombosis. We adjusted our findings for classical 
venous thrombosis risk factors, for unhealthy life style and for 
immobilization to determine whether the associations could be explained by 
confounding through these factors. The combined effect of prothrombotic 
genes and pneumonia was evaluated through a stratification analysis.  
Pneumonia was associated with an increase in risk for venous thrombosis (5 
times more likely to have venous thrombosis, odds ratio 5.0; 95% CI, 3.9-
6.3). This risk was higher when pulmonary embolism was considered (odds 
ratio 7.9; 95% CI, 6.1-10.3, for pulmonary embolism with or without deep 
vein thrombosis) than when deep vein thrombosis only was considered (odds 
ratio 3.0; 95% CI, 2.2-4.0). None of the adjustments substantially changed 
the results. A joint positive effect was observed for factor V Leiden 
/prothrombin G20210A and pneumonia to venous thrombosis risk (odds 
ratios > 17).  
This study shows that pneumonia is a moderate to strong risk factor for 
venous thrombosis. This study also provides evidence that the association 
between infectious or inflammatory disease and venous thrombosis cannot 




In Chapter 3, we had the opportunity to study circannual variability of 
venous thrombosis in three regions (i.e. Milan/ Italy, Leiden/the Netherlands 
and Tromsø/Norway). These three regions have a similar climate type 
(Köppen classification Cfa, Cfb, Cfb/Dfc, respectively), and are similarly 
situated around sea level, but differ in the annual temperature, which is 
highest in Milan, lower in Leiden and lowest in Tromsø. The regions are 
therefore matched on demographic and climate variables, but differ in terms 
of temperature, sunlight and air pollution. Three different data set were used 
in the analysis, the Multiple Environmental and Genetic Assessment 
(MEGA) study (Leiden), the Tromsø study (Tromsø) and from the 
Lombardy region (Milan). We evaluated the absolute risk differences 
between seasons of prevalent venous thrombosis. 
Approximately half of the patients were men, and the mean age at time of 
thrombosis was 49 years (interquartile range 39-61). In all three studies, the 
prevalence of venous thrombosis was lowest in Spring as compared with the 
other seasons (absolute risk difference - 2.3%, 95% CI, -4.0 to -0.7). The 
absolute risk difference (taking Spring as a reference group) was -2.6% 
(95% CI, -4.3 to -1.0) to Winter, -2.2% (95% CI -3.8 to -0.6) to Summer and 
-2.2% (95% CI, -3.8 to -0.5) to Autumn, respectively. When unprovoked 
events, or incident pulmonary embolism, or men only were analyzed 
separately, a similar pattern was observed, that is: a lower prevalence of 
thrombosis in Spring than in the other seasons. 
We observed a difference in the distribution of venous thrombosis over the 
seasons in all three regions, wherein the prevalence was lowest in Spring. 
Though the absolute difference of venous thrombosis between Spring and 
the other seasons was statistically significant, the clinical relevance is 
negligible. The causal relation between weather and venous thrombosis 
incidence could be real, although a causal interpretation of this finding is 
hard to provide. To proof causality, one would like to know an intervention 
strategy, and the intervention “Spring” seems too ambiguous to use as an 
intervention tool. Nevertheless, we inferred some things from this study. 
First, our findings cannot be explained by a sole linear increase of 
temperature. Second, transient infections are also not very likely to explain 
our results. Third, the results are also probably not explained by sunlight 
exposure. Fourth, air pollution, seemed also not to explain the difference in 
risk over the seasons. Finally, a referral bias seemed also unlikely. To 
conclude,  in our study the risk of venous thrombosis was different between 
the seasons. We were unable to provide a reason for the difference in venous 
thrombosis risk between the seasons. 
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In Chapter 4 we investigated whether the presence of factor (F)V Leiden 
with blood group non-O modifies the risk for venous thrombosis in 
individuals with different body mass index strata in a case-control study 
(N=11253). We observed that a progressive increase in body mass index was 
associated with an ever increasing risk for venous thrombosis, odds ratio 1.9 
(95%CI, 1.6-2.3) for those in the upper tertile, as compared with individuals 
in the first body mass index tertile, blood group O, and no FV Leiden (the 
reference group). The addition of FV Leiden and blood group non-O in the 
model increased the risk in all body mass index tertiles; odds ratios were 3.8 
(95%CI, 3.2-4.6) in the third body mass index tertile of individuals with 
blood group non-O, and 5.4 (95% CI, 3.5-8.5) in the third body mass index 
tertile of individuals with FV Leiden, respectively. When both FV Leiden 
and blood group non-O were present, odds ratios were 9.1 (95% CI, 5.9-
14.0) in the first body mass index tertile, 9.4 (95% CI, 6.6-13.5) in the 
second body mass index tertile, and 12.5 (95% CI, 8.9-17.6) in the third 
body mass index tertile. In conclusion, individuals with a high body mass 
index, blood group non-O or factor V Leiden are at higher thrombosis risk 
than expected when these prothrombotic factors are analyzed separately. The 
high risks of venous thrombosis in some subgroups may justify targeted 
screening and thromboprophylaxis decisions.  
 
In Chapter 5 we aimed to determine whether protein S deficiency is 
associated with venous thrombosis in a population-based case-control study 
(n=5317) as it is in thrombophilic family studies. Subjects were regarded 
protein S deficient when protein S levels were <2.5th percentile of the 
controls. Free- and total protein S deficiency was not associated with venous 
thrombosis: free protein S <53 U/dL, odds ratio [OR] 0.82 (95%CI, 0.56-
1.21) and total protein S <68 U/dL, OR 0.90 (95%CI, 0.62-1.31). 
Restriction, stratifications and adjustments for possible confounders did not 
chance findings. When lower cut-off values were applied, it appeared that 
individuals at risk of venous thrombosis could be identified at levels <0.10th 
percentile of free protein S (<33 U/dL, OR 5.4; 95% CI, 0.61-48.8). In 
contrast, even extremely low total protein S levels were not associated with 
venous thrombosis. PROS1 was sequenced in 48 subjects with free protein S 
level <1st percentile (<46 U/dL), and copy number variations were 
investigated in 2718 subjects, including all subjects with protein S (free or 
total) <2.5th percentile. Mutations in PROS1 were detected in five patients 
and five controls reinforcing the observation that inherited protein S 
deficiency is rare in the general population. Our results show that protein S 
testing and subsequent testing on PROS1 mutations should not be considered 
in unselected patients with venous thrombosis. 
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Part	  II:	  Risk	  factors	  for	  recurrent	  venous	  
thrombosis	  
Chapter 6 is a review which outlines what is currently known about the 
epidemiology of recurrent venous thrombosis, and focuses in more detail on 
potential new risk factors for venous recurrence. The general implications of 
these findings in patient management are discussed. Venous thrombosis, 
including deep vein thrombosis and pulmonary embolism, is a common 
disease that frequently recurs. Recurrence can be prevented by anticoagulants, 
but this comes at the risk of bleeding. Therefore, prevention of recurrent 
venous thrombosis will be more profitable if it becomes possible both to 
identify more precisely those individuals who are at risk of recurrent venous 
thrombosis and to quantify the risk to which they are exposed. Consideration 
of the discussed new risk factors for recurrence may allow us a more optimal 
use of prophylactic strategies against recurrent venous thrombosis. 
  
In Chapter 7, we evaluated the possibility of new strategies to classify the 
risk for recurrent venous thrombosis. Some patients may have experienced 
many venous thrombosis risk situations during their life time without 
developing venous thrombosis, while others may have experienced few of 
such risk factors and then develop venous thrombosis idiopathically or after 
a single provoked risk factor. We hypothesized that those who had 'survived' 
many risk situations without developing an event would, after a first venous 
thrombosis, have a low recurrence risk. Patients who were included in a 
Brazilian tertiary hospital were followed after anticoagulation withdrawal for 
a first venous thrombosis. Patients with indication for indefinite 
anticoagulation were not included. The primary end point was objective 
recurrent venous thrombosis.  
Recurrent venous thrombosis was recorded in 7% of 378 eligible patients. 
Patients with a provoked first event and positive past risk situations for 
venous thrombosis had an incidence rate of recurrence of 1.16 (95% 
confidence interval [CI], 0.47-2.39) per 100 patient-years. The incidence rate 
ratio of this subgroup compared with patients with a provoked event without 
other past risk situations for venous thrombosis was 1.1 (95% CI, 0.3-4.4). 
This incidence rate ratio was 3.3 (95% CI, 1.3-8.7) in patients with an 
unprovoked event and positive past risk situations and 5.1 (95% CI, 1.6-
16.1) in patients with an unprovoked event and no past risk situations.  
In this study the risk for recurrence was related with the nature of a first 
provoked or unprovoked event and only slightly with the presence of other 
past risk situations for venous thrombosis. Asking a patient about past 
exposure of venous thrombosis risk factors long before the occurrence of a 
first venous thrombosis occurred, does not provide information to classify 
patients at lower risk for recurrence of venous thrombosis.  
Summary and Discussion 
159 
In Chapter 8, we reevaluated the same cohort described in chapter 7, but 
now with a longer follow up. The objective was the same, i.e., to try and find 
a variable that could help us in the decision about to keep or not the 
anticoagulation treatment.  
Patients, after a first confirmed venous thrombosis event, were followed for 
an average of 43 months after suspension of anticoagulation and the primary 
end point was objective recurrent venous thrombosis. Patients with a 
provoked first event and positive past risk situations had an incidence rate of 
recurrence of 1.26 (95% CI, 0.60-2.31) per 100 patient-years and this was 
our “reference group”. The incidence rate ratio of patients with a provoked 
event without other past risk situations for venous thrombosis compared with 
the reference group was 0.8 (95% CI 0.2-2.9). This incidence rate ratio was 
2.8 (95% CI, 1.2-6.5) in patients with an unprovoked event and positive past 
risk situations and 7.1 (95% CI, 3.0-17.1) in patients with an unprovoked 
event and no past risk situations versus our control group. The incidence rate 
ratio was 2.5 (95% CI, 1.1-5.9) for patients without past risk situation 
compared with those with these history when only idiopathic first events 
were evaluated. 
We conclude that previous risk situations for venous thrombosis affected 
recurrence risk only in patients with an unprovoked first event. 
 
In Chapter 9, we performed a prospective cohort study to assess the risk of 
recurrence in patients with provoked and unprovoked first venous 
thrombosis, related to the presence or absence of prothrombotic alterations. 
Since prothrombotic alterations can be demonstrated in at least 50% of 
patients with venous thrombosis, testing patients with a first venous 
thrombosis has gained great interest. Subjects were patients with one 
previous venous thrombotic event followed from April 2000 to July 2011 at 
the University Hospital of 
Universidade Federal de Minas Gerais. The study cohort included 378 
patients and the total follow-up was 1573 person-years, with a median 
follow-up of 43 months. 
Laboratory test information was available for factor VIII activity, 
homocysteine, factor V Leiden, (rs6025), prothrombin G20210A 
(rs1799963) and blood group. We analysed these risk factors individually 
and grouped. We considered high factor VIII as levels > 150 IU/dL in two 
occasions after at least three months apart. Similarly a high level of 




Recurrent venous thrombosis occurred in 35 (9%) patients, for an incidence 
of 22 per 1000 person-years. The relative risk estimates were approximately 
1 for all comparisons showing no association between venous thrombosis 
recurrence risk and prothrombotic laboratory abnormalities. In those with 
abnormal prothrombotic tests and an unprovoked first event there was a 4-
fold increase in the recurrence risk. From our results, we concluded that 
thrombophilia testing in all patients with a first venous thrombosis is not 
useful. Future studies are required to further elucidate whether patients with 
a first unprovoked event and a negative result for prothrombotic 
abnormalities are at reduced risk for venous thrombosis recurrence. 
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DISCUSSION	  
Venous thrombosis is a common disorder that can affect apparently healthy 
individuals as well as hospitalized patients. One estimate is that there are 
worldwide about 10 million people suffering from venous thrombosis per 
year with admission to hospital, with an equal incidence in high-income and 
low-income countries, but with more deaths in the latter (ISTH Steering 
Committee for World Thrombosis Day; J Thromb Haemost. 2014;12:1580–
1590). Venous thrombosis is probably best understood as a multicausal 
disease in which more than one genetic or environmental condition coincides 
to produce clinically apparent thrombosis.  
Venous thrombosis can easily be prevented by anticoagulants, but at the risk 
of side-effects, most notably hemorrhage. Anticoagulant-associated bleeding 
is the number one cause of iatrogenic admission to hospital. Hence, 
prevention should be tailored to those individuals who have the highest risk 
to develop venous thrombosis. 
Searching for risk factors or a combination of concurrently present risk 
factors can improve our capacity of identification the risk situations in 
specific individuals, therefore reaching a personalized relation between risk 
and benefits for thromboprophylaxis applications. The aim of this thesis was 
to understand better and to search for such risk situations. 
In this thesis, it was shown that pneumonia increases the risk for venous 
thrombosis. The positive interaction between pneumonia and factor V 
Leiden or prothrombin G20210A besides assets our findings, and should be 
taken into consideration for thromboprophylaxis decisions that should be 
studied in clinical trials. In our seasons study (chapter 3) we observed a 
difference in the distribution of venous thrombosis over the year, wherein 
the prevalence was lowest in Spring, and somewhat similar over the other 
seasons. The difference of venous thrombosis between spring and the other 
seasons was (2%). Although this difference may seem relevant, we 
concluded from this study that the clinical applicability is negligible, as we 
also explained in a rebuttal (see J Thromb Haemost. 2013;11:570-2) to a 
comment (in J Thromb Haemost. 2013;11:568-70). First, we explained that 
when we considered spring as our reference season (23.2% of all events 
occurred in spring), and compared this finding with winter (25.9% of all 
events occurred in winter), we would have found a 25.9/23.2 × 100 = 12% 
higher rate of venous thrombosis in winter than in spring. This relative 
increase was in the same range as the authors in the rebuttal found for risk of 
venous thrombosis in winter as compared with spring (19% higher rate). 
Next, we explained that a relative increase of a first venous thrombosis of 
even 19% on a bad winter day as compared with a good summer day can 
ever be clinically useful. As the absolute risk of venous thrombosis is 1 in 
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1000 persons per year or 1/365.25 in 1000 persons per day, a relative 
increase of 19% of a bad winter day as compared with a good summer day 
would mean that about 5000 persons (1000/0.19) would need to be treated 
with a good summer day annually to prevent 1 venous thrombotic event 
which is about 1.8 million per day to prevent one venous thrombosis event. 
If we could give one person a summer season instead of a winter season, we 
would need to give this to 400 000 people to prevent one thrombotic event, 
and likewise for other interventions. Even if we were able to completely 
replace 3 months of Dutch winter by summer, for 3 months, we would need 
to maintain this for hundreds of years to prevent one case of thrombosis. 
Furthermore, the intervention ‘good summer day’, however desirable, seems 
a difficult tool to introduce into clinical practice. Though we tried, we were 
unable to provide a reason for the difference in venous thrombosis risk 
between the seasons. The latter is somewhat disappointing, as according to 
the principle of sufficient reason everything must have a reason or a cause. 
Others may be more successful than we were here. By courtesy of professor 
le Cessie, another issue about the calculated “2%”should be mentioned  here, 
that is that spring was not prespecified as being the season in which venous 
thrombosis would have occurred less as compared with the other seasons and 
that for this reason it would have been better to compare the four observed 
percentages in the four different seasons to the expected percentages (25; 25; 
25; 25), yielding a p-value of 0.03. 
That venous thrombosis is a multicausal disease was (again) shown in 
chapter 4, where it was shown that individuals with a high body mass index, 
blood group non-O or factor V Leiden are at a 12.5 fold higher venous 
thrombosis risk than when these prothrombotic factors are absent. When 
other transient risk situations such as hormone use, immobilization and 
recent travel were analyzed in subgroups, the same pattern was observed. As 
the daily life situations described above are frequent, even a small increase 
in relative risks can be clinically relevant.  
Changing paradigms, these two words help to discuss Chapter 5. Although 
individuals with very low levels of free protein S appeared to be at  
increased risk of unprovoked venous thrombosis (odds ratio 2.31, 95%CI, 
1.06-5.05), the prevalence of venous thrombosis patients with such levels 
was very low (0.4%), making it unpractical to use free protein S levels to 
help identify patients at risk in a clinical setting. Total protein S levels were 
not able to identify subjects at risk of venous thrombosis even when these 
levels are very low. Therefore, a relevant question, about the utility of 
searching for protein S deficiency in any patient with venous thrombosis is 
answered with “No”. Maybe only patients with venous thrombosis who 
originate form thrombophilic families should be screened for protein S 
deficiency.  
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The optimal duration of anticoagulant therapy in patients with a first episode 
of venous thrombosis, occurring in the absence of antecedent major risk 
factors, is unknown. Based on a 5-year cumulative risk of disease recurrence 
of 25 to 30% in these patients, current American College of Chest Physicians 
guidelines recommend at least 3 months of treatment with a vitamin K 
antagonist, and an option for life-long anticoagulation in patients at low risk 
of bleeding. While preventing most recurrences, this approach has some 
drawbacks. Whereas the risk of recurrence appears to diminish with time, the 
risk of anticoagulant related hemorrhage increases with ongoing 
anticoagulation and advancing age. Hence, the net clinical benefit of 
indefinite anticoagulation may vary considerably over the long term. The 
risk of recurrent venous thrombosis may be lower in certain patients. 
Therefore, at least in some patient subgroups, the risk of recurrence 
approximates the annual risk of anticoagulant-related major hemorrhage. 
Another challenge that was faced in this thesis was to identify venous 
thrombosis patient groups that may have a low risk of recurrence and could 
for this reason receive anticoagulants for only a short time.  
We hypothesized  (in chapters 6-8) that patients at risk for recurrent venous 
thrombosis, who had experienced transient provoked risk factors previously, 
yet not developed thrombosis at that time, would have a lower risk of 
recurrence than those whose first (provoked or unprovoked) event was not 
preceded by provoked risk factors. This hypothesis was based on the 
thrombosis potential model, first described by Frits Rosendaal in 1999, 
where all individuals have a thrombosis threshold and a thrombosis 
potential; when this limit is crossed venous thrombosis occurs. Therefore, if 
someone has already been pushed through a risk situation for venous 
thrombosis in the past and an event did not happen, it suggests that this 
person has a high thrombosis threshold (or a low thrombosis potential) and, 
therefore, probably a lower risk for venous thrombosis recurrence. From 
chapters 7 and 8 we concluded that the absence of past exposure to risk 
factors for venous thrombosis long before the occurrence of a first venous 
thrombosis occurred, may be used to classify patients with a first 
unprovoked venous thrombosis at higher risk for recurrence of venous 
thrombosis. Although the cohort in which this result originated from was 
validated through stratified analyses using risk factors for recurrence already 
described, the finding needs to be validated by other groups and in different 
populations before it can be incorporated in clinical practice.  
We finally assed whether identification of prothrombotic abnormalities 
could lead to reduced venous thrombosis recurrence due to changes in 
clinical management, such as prolongation of initial anticoagulant treatment 
or intensified prophylaxis during high-risk situations. However, as also 
shown by previous studies, no different recurrence risk was found. Although 
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we observed that patients with a first unprovoked event and prothrombotic 
abnormalities had an increased risk of recurrence, numbers were small and 
the confidence interval was wide. Another point is that we evaluated 
thrombophilias as one group, “present or not”, and that we could not 
simultaneously test for all concurrent known laboratory abnormalities related 
with an increased risk for first venous thrombosis. It has recently been 
shown in the MEGA follow-up study that such a strategy, may, after all, be 
useful in the prediction of recurrent thrombosis. Therefore, the finding in 
chapter 9 must be observed with restrictions.  
In conclusion, in this thesis, the thrombosis potential model was successfully 
applied to several known risk factors for venous thrombosis to better 
understand why first and recurrent venous thrombosis can develop in an 
individual patient. Thanks to the old concept of the thrombosis potential 
model, which supposes that patients with past provoking risk factors should 
have a lower risk of recurrent venous thrombosis than those whose first 
(provoked or unprovoked) event was not preceded by provoked risk factors, 
has led to the new insight for clinicians that these past provoking risk factors 
might be of use to stratify patients at low or high risk of recurrent venous 
thrombosis to which they can adapt thrombosis prevention strategies.  
 
Future	  directions:	  	  
The most important risk factor for recurrence is the presence of any triggering 
factor during or close to the venous thrombotic event. Therefore, the discovery 
of unknown/new risk factors in patients with unprovoked venous thrombosis 
will add to our ability to predict recurrence. An easy, costless, anamnestic test 
for physicians is to ask patients with venous thrombosis about preceding 
triggering factors, yet not developed thrombosis at that time. These patients 
had a lower risk of recurrence than those whose first (provoked or 
unprovoked) event was not preceded by provoked risk factors in this thesis 
and may, for this reason, be candidates who do not need to be treated with 
anticoagulants for a prolonged (indefinite) time. Nevertheless, one cannot be 
confident that this finding, as well as all other findings that are reported in this 
thesis, will prove true in the long run. For this reason one needs replication 
studies, and it is to be hoped that the results from this thesis will lead to such 
replication studies. That replication studies are vital to science and progress is 
not only true for the studies that are reported in this thesis: it is true for all 
studies, including clinical trials from pharmaceutical companies. The reason to 
specifically mention these clinical trials here, is because we are now entering 
an era in which the direct oral anticoagulants (DOACS) are introduced as 
anticoagulant treatment to patients with venous thrombosis. These trials 
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showed (for the specific DOAC classes) that treatment with DOAC was non-
inferior to vitamin K antagonist treatment. They are now given to patients with 
venous thrombosis on a global scale, but none of these studies have been 
replicated thus far, for which the reason is unknown. It could be due to costs. 
Trials are expensive and are very time consuming enterprises. It could also be 
because patients, researchers, clinicians and/or politicians think that replication 
studies are unnecessary: a waste of time, effort and money. If the latter is the 
reason to not replicate trials (and other studies), then we cannot be sure that 
medical science is built on a solid foundation. Indeed, researchers showed in 
Nature (Begley et al, Nature 2012) that in hemato-oncology 47 out of 53 
highly promising results from pharmaceutical trials could not be replicated. 
And the epidemiologist Ioannidis has argued that failure or non-willingness to 
replicate study results in medical science is a reason why most published 
research findings are false (Ioannidis, PLos Med 2005). It is therefore not with 
modesty, but with urgency to draw the attention to the necessity to replicate 
research findings from all theses, including this thesis. Following such a 



















Veneuze trombose (waaronder diepe veneuze trombose en longembolie 
wordt verstaan) is een vaak voorkomende aandoening in zowel de algemene 
bevolking als bij patiënten die zijn opgenomen in het ziekenhuis. 
Wereldwijd krijgen ongeveer 10 miljoen mensen per jaar veneuze trombose 
waarvoor zij tijdelijk dienen opgenomen te worden in een ziekenhuis. 
Trombose komt even vaak voor in landen met een hoog gemiddeld inkomen 
als in ontwikkelingslanden, ofschoon het aantal doden ten gevolge van 
trombose hoger is in ontwikkelingslanden (ISTH Steering Committee for 
World Thrombosis Day; J Thromb Haemost. 2014;12:1580–1590). Het 
ontstaan van veneuze trombose kan het best worden begrepen als een 
aaneenschakeling van genetische en omgevingsfactoren, waar een bepaalde 
omstandigheid de spreekwoordelijke druppel de emmer doet overlopen 
(multicausaal model).  
Met antistollingsmiddelen kan veneuze trombose relatief gemakkelijk 
voorkomen worden, maar dergelijke middelen hebben bijwerkingen, waarbij 
de meest gevreesde bijwerking ernstige (orgaan)bloedingen zijn. Bloedingen 
ten gevolge van antistollingsmiddelen zijn de meest voorkomende oorzaak 
van ziekenhuisopnamen ten gevolge van bijwerkingen van medicijngebruik. 
Daarom worden deze middelen liefst alleen voorgeschreven aan mensen die 
een intrinsiek hoog risico hebben op het krijgen van veneuze trombose. Het 
identificeren van nieuwe risicofactoren van trombose of het beoordelen van 
interactie tussen bekende risicofactoren voor trombose kunnen ons begrip 
waarom iemand veneuze trombose krijgt, vergroten. Hierdoor kan 
vervolgens een individuele inschatting worden gemaakt wie er wel en wie 
niet een verhoogd risico heeft op het krijgen van veneuze trombose. Daarna 
kan empirisch afgewogen worden wie er antistollingsmiddelen voor een 
bepaalde duur moeten krijgen vanwege het hoge  risico op trombose . Het 
doel van dit proefschrift is om dergelijke hoog-risico situaties te 
identificeren en beter te begrijpen .  
Dit proefschrift heeft aangetoond dat longontsteking (pneumonie) het risico 
op het krijgen van veneuze trombose verhoogt . Mensen met longontsteking 
die een onderliggende genetische variant dragen die het risico op veneuze 
trombose verder verhoogt  (zoals  factor V Leiden of protrombine G20210A 
variant) hebben veruit het hoogste risico op het krijgen van veneuze 
trombose (hoofdstuk 2). Dit resultaat bevestigt dat veneuze trombose een 
multicausale ziekte is, en dat vooral mensen met een genetische variant als 
factor V Leiden of protrombine G20210A mogelijk baat hebben bij het 
krijgen van antistolling ten tijde van een longontsteking. In hoofdstuk 3 
wordt een verschil aangetoond in de distributie van het ontstaan van veneuze 
trombose over de seizoene: in de lente komt veneuze trombose minder vaak 
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voor dan in   de andere drie seizoenen. Het verschil in prevalentie  is 2% ten 
faveure van de lente ten opzichte van de andere seizoenen. Waarom dit 
verschil aanwezig is, kon niet met deze studieopzet aangetoond worden. Wel 
kon de ‘klinische relevantie’ van dit verschil worden toegelicht aan de hand 
van een getallenvoorbeeld. Dat hebben wij gedaan nadat anderen  zich sterk 
hadden gemaakt dat een verschil van 2% over de seizoenen klinische 
consequenties zou kunnen hebben (J Thromb Haemost. 2013;11:568-72). 
Ten eerste legden wij uit dat een prevalentie van ziekte niet gelijk is aan het 
optreden van ziekte. Een prevalentie van 2% meer trombose komt overeen 
met een relatieve toename van 10-20%. Gezien het absolute risico op het 
krijgen van veneuze trombose 1 per 1000 per jaar is, is  het risico op veneuze 
trombose 1/365.25 per 1000 per dag is (aangezien een jaar gemiddeld 365.25 
dagen telt). Met deze getallen rekenden wij uit dat wat betreft  het wisselen 
van een druilerige koude winterse dag met een mooie zonrijke dag er 
ongeveer 5000 mensen een jaar lang met een mooie zonrijke dag dienen te 
worden ‘behandeld’ om één trombose te voorkomen of 1.8 miljoen mensen 
één dag moeten worden ‘behandeld’ met een mooie zonrijke dag om één 
veneuze trombose te voorkomen.  Dit getallenvoorbeeld toont aan dat de 
klinische relevantie van deze bevinding afwezig is, ofschoon uiteraard een 
mooie warme Braziliaanse lentedag te prefereren is boven een koude, 
druilerige Nederlandse winterdag.  
Dat veneuze trombose het best omschreven kan worden als een multicausale 
ziekte werd (wederom) aangetoond in hoofdstuk 4, waar mensen met een 
hoog BMI, bloedgroep niet-0 en factor V Leiden een 12.5-voudig verhoogd 
risico hebben op het krijgen van veneuze trombose in vergelijking met 
degenen die deze risicofactoren niet bezitten. In subgroepanalysen toonden wij 
aan dat een zelfde verhoogd risico op trombose aanwezig is bij vrouwen die de 
anticonceptiepil slikken, recentelijk langdurig gereisd hebben of die tijdelijk 
geïmmobiliseerd zijn. Aangezien dezefactoren vaak aanwezig zijn binnen de 
bevolking, kunnen  deze hoge relatieve risico’s klinisch relevant  zijn. 
Veranderend paradigma, deze twee woorden helpen in het samenvatten van 
hoofdstuk 5. Een familiaire afwijking in het hebben van een te lage 
hoeveelheid in het bloed  van anticoagulant eiwit “proteïne S” levert een 
hoog risico op het krijgen van veneuze trombose. Dit vonden wij ook terug, 
zoals beschreven in hoofdstuk 5, waarbij mensen uit de algemene bevolking 
met erg lage bloedwaarden van vrij proteïne S een verhoogd risico bleken te 
hebben op het krijgen van veneuze trombose (odds ratio 2.31, 95%BI, 1.06-
5.05). Echter, de prevalentie van deze afwijking in patiënten met 
onverklaarde veneuze trombose is laag (0.4%). Een dergelijke lage 
prevalentie maakt het onwaarschijnlijk dat het testen op te laag vrij proteïne 
S in alle patiënten met veneuze trombose zinvol kan zijn: de vooraf-trefkans 




proteïne S antigeen leverde geen enkel aanknopingspunt op dat mensen uit 
de algemene bevolking een verhoogd risico hebben op het krijgen van 
veneuze trombose. Deze bevindingen suggereren dat alleen mensen met 
veneuze trombose waarbij deze ziekte vaak voorkomt in de familie getest 
zouden kunnen worden op proteïne S.  
Het is onbekend wat de optimale behandeling met antistollingsmiddelen is 
bij patiënten die een eerste veneuze trombose hebben doorgemaakt zonder 
daarbij eerder blootgesteld  te zijn geweest aan tromboserisicofactoren. 
Hoewel de internationale richtlijn van de ‘American College of Chest 
Physicians’ adviseert om iedereen met trombose minimaal 3 maanden te 
behandelen en mogelijk levelnslang voor degenen die een laag basisrisico 
hebben om een bloeding te krijgen onder antistollingstherapie, is dit advies 
niet zonder risico’s. Enerzijds neemt het jaarlijkse risico op het krijgen van 
een nieuwe trombose met de tijd af, maar anderzijds neemt het jaarlijkse 
bloedingsrisico ten gevolge van antistollingstherapie met de leeftijd toe. 
Daarom is het onzeker of mensen met een eerste veneuze trombose wel 
levenslang antistollingstherapie moeten blijven gebruiken. Dit geldt zeker 
voor patiëntengroepen bij wie het basisrisico op  een nieuwe veneuze 
trombose laag is. In hoofdstuk 6-8 wordt getracht om van patiënten met 
veneuze trombose met  anamnestisch verkregen informatie het recidief risico 
in te schatten. Degenen bij wie dit risico als laag wordt ingeschat, zouden na 
3-6 maanden veilig kunnen stoppen met antistollingstherapie. In deze 
hoofdstukken wordt gebruik gemaakt van het ‘trombose potentiaal model’ 
dat in 1999 voor het eerst is beschreven door Frits Rosendaal. De hypothese 
was dat patiënten met veneuze trombose die eerder geen trombose hadden 
ontwikkeld terwijl ze toch eerder een ‘hoogrisico’ situatie hadden 
doorgemaakt,   een lager risico zouden hebben op   een recidieftrombose dan 
degenen die niet eerder blootgesteld waren aan een dergelijke hoogrisico 
situatie. Uit hoofdstuk 7 en 8 blijkt dat patiënten met dergelijke 
‘hoogrisicofactoren’ in de voorgeschiedenis, inderdaad een lagere kans 
hebben op  een recidieftrombose. In beide hoofdstukken wordt geadviseerd 
om deze studies eerst te repliceren in andere studies alvorens er klinische 
consequenties aan verbonden kunnen worden.  
In het laatste hoofdstuk van dit proefschrift (hoofdstuk 9) werd beoordeeld 
of protrombotische bloedafwijkingen het risico op recidief veneuze trombose  
verhogen. Evenals eerdere studies naar dit onderwerp werd geen effect 
gevonden op het optreden van recidieftrombose bij patiënten met 
protrombotische bloedafwijkingen. Aangezien de aantallen in deze studie 
klein waren kon er geen onderscheid worden gemaakt tussen het simultaan 
bestaan van meerdere protrombotische afwijkingen en het optreden van een 
recidief, maar slechts kon  worden beoordeeld of het al dan niet hebben van 
een of meerdere protrombotische afwijkingen het recidief tromboserisico 
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verhoogt. Een grotere studie in de MEGA follow-up heeft aangetoond dat de 
strategie waarbij meerdere protrombotische factoren bij elkaar worden 
opgeteld om het recidief risico te bepalen, wel succesvol kan zijn in het 
voorspellen van wie wel en wie niet een recidieftrombose krijgt. De 
interpretatie van hoofdstuk 9 moet daarom  voorzichtig zijn.  
In conclusie: in dit proefschrift is het multicausale trombosepotentiaalmodel 
verscheidene malen succesvol toegepast om te begrijpen of en waarom 
eerste en recidief veneuze trombose kan ontstaan in een individuele patiënt. 
Met dank aan het oude concept van het trombosepotentiaalmodel, dat 
veronderstelt dat patiënten met veneuze trombose die eerder een hoog risico 
situatie hebben doorgemaakt, en toch geen trombose kregen, kon aangetoond 
worden dat deze theorie de praktijk volgt. Dit kan leiden tot het nieuwe 
inzicht bij clinici dat het uitvragen van deze eerdere hoog risicofactoren van 
invloed kan zijn in het bepalen welke patiënt met veneuze trombose al dan 
niet langdurig antistollingstherapie behoort te krijgen. 
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